INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4501, 0, 'Ziprasidone', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4502, 0, 'Ziprasidone', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4503, 0, 'Ziprasidone', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4504, 0, 'Ziprasidone', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4505, 0, 'Ziprasidone', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4506, 0, 'Ziprasidone', 'Priapism', 'Atypical antipsychotic agents with alpha-adrenergic blocking effects may cause priapism.  The condition is characterized by prolonged, often painful erections lasting longer than 4 hours.  If not treated promptly, priapism can cause irreversible damage to the erectile tissue.  Therapy with these agents should be administered cautiously in patients with a history of priapism, conditions that may predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia, thalassemia), or anatomical deformations of the penis (e.g., angulation, cavernosal fibrosis, Peyronie''s disease).  Patients who experience an erection lasting longer than 4 hours, whether painful or not, should immediately discontinue the drug and seek emergency medical attention.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4507, 0, 'Ziprasidone', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4508, 0, 'Ziprasidone', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4509, 0, 'Ziprasidone', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4510, 0, 'Ziprasidone', 'Liver Diseases', 'Most neuroleptic agents are extensively metabolized by the liver.  The plasma concentrations of these agents may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with neuroleptic agents should be administered cautiously in patients with significant liver disease.  Lower initial dosages and slower titration may be appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4511, 0, 'Ziprasidone', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4512, 0, 'Ziprasidone', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4513, 0, 'Zolpidem', 'Alcoholic Intoxication', 'Anxiolytic, sedative, and hypnotic agents should generally not be given to patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of these agents may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with such agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4514, 0, 'Zolpidem', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4515, 0, 'Zolpidem', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4516, 0, 'Zolpidem', 'Liver Diseases', 'Zolpidem is primarily metabolized by the liver.  The plasma concentrations and half-life of zolpidem have been shown to increase substantially in the presence of chronic hepatic insufficiency.  Therapy with zolpidem should be administered cautiously in patients with impaired hepatic function.  Since many of the drug''s adverse effects may be dose-related, especially those involving the central nervous system or gastrointestinal tract, an initial dosage of 5 mg is recommended for these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4517, 0, 'Zolpidem', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4518, 0, 'Zolpidem', 'Respiratory Insufficiency', 'Oral anxiolytic, sedative, and hypnotic agents may cause respiratory depression and apnea when given in high dosages or following acute overdose.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4519, 0, 'Zolpidem', 'Kidney Diseases', 'Zolpidem is extensively metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Limited data suggest that the pharmacokinetic disposition of zolpidem is not altered in the presence of renal insufficiency or even end-stage renal disease, and that there is no accumulation of unchanged drug after repeated dosing.  However, the effects of possible metabolite accumulation have not been studied.  While dosage adjustments are generally not required, close monitoring is recommended in patients with impaired renal function treated with zolpidem.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4520, 0, 'Bevacizumab', 'Fistula', 'Bevacizumab may cause fatal fistula formation involving tracheoesophageal, bronchopleural, biliary, vaginal, renal and bladder sites.  Permanently discontinue bevacizumab in patients with tracheoesophageal fistula or any Grade 4 fistula.  Discontinue bevacizumab in patients with fistula formation involving an internal organ.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4521, 0, 'Bevacizumab', 'Peptic Ulcer Perforation', 'Inhibitors of vascular endothelial growth factor receptors (VEGFR) may cause gastrointestinal perforation and fistulae.  Avoid use of these agents in patients with ovarian cancer who have evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction.  Permanently discontinue these agents in patients with gastrointestinal perforation.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4522, 0, 'Bevacizumab', 'Hemorrhage', 'Bevacizumab impairs wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Bevacizumab should not be started for at least 28 days after surgery and until the wound is fully healed.  Discontinue bevacizumab in patients with wound healing complications requiring medical intervention or in patients who develop necrotizing fasciitis.  Do not administer this agent to patients with recent history of hemoptysis and discontinue bevacizumab in patients with hemorrhage.  Caution is recommended when using this agent in patients at increased risk of bleeding or before surgery and is recommended to stop therapy for at least 28 days prior to elective surgery.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4523, 0, 'Bevacizumab', 'Hypertension', 'Inhibitors of vascular endothelial growth factor receptors (VEGFR) have been associated with severe increases in blood pressure.  Therapy with these agents should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment, regularly during treatment and after discontinuation in patients with bevacizumab -induced or -exacerbated hypertension.  Temporarily suspend these agents in patients with severe hypertension that is not controlled with medical management.  Discontinue these agents in patients with hypertensive crisis or hypertensive encephalopathy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4524, 0, 'Bevacizumab', 'Posterior Leukoencephalopathy Syndrome', 'Posterior Reversible Encephalopathy Syndrome (PRES) has been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR) in clinical studies.  PRES is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances.  It is recommended to discontinue these agents in patients developing PRES.  The safety of restarting therapy is not known.  Cation is recommended if therapy is reinitiating in patients previously experiencing PRES.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4525, 0, 'Bevacizumab', 'Proteinuria', 'The incidence and severity of proteinuria is increased in patients taking inhibitors of vascular endothelial growth factor receptors (VEGFR).  Therapy with these agents should be administered cautiously in patients with renal dysfunction.  Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated.  It is recommended to temporarily suspend these agents in patients with moderate to severe proteinuria and to discontinue therapy in patients with nephrotic syndrome.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4526, 0, 'Bevacizumab', 'Thromboembolism', 'Venous and arterial thromboembolic events (VTE and ATE), some fatal, have been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR).  Caution is recommended when using these agents in patients with a reported history of VTE or ATE.  These agents should be discontinued in patients with serious or life-threatening VTE or ATE, including pulmonary embolism.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4527, 0, 'Bethanechol', 'Bronchial Spasm', 'The use of cholinergic agonists is contraindicated in patients with uncontrolled reactive airway disease.  Cholinergic agonists inhibits the hydrolysis of acetylcholine.  The enhanced effect of acetylcholine produces constriction of the bronchi, increased bronchial secretions, and bronchospasm.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4528, 0, 'Bethanechol', 'Heart Failure', 'The use of cholinergic agonists, such as bethanechol and pilocarpine, is contraindicated in patients with pronounced bradycardia, hypotension/hypertension, coronary artery disease or conduction disorders.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4529, 0, 'Bethanechol', 'Urinary Bladder Neck Obstruction', 'The use of cholinergic agonists is contraindicated in patients with peptic ulcers, mechanical GI obstruction, acute GI inflammatory conditions, or urinary obstruction.  Cholinergic activity may result in an increase in gastric acid secretion, GI motility, and gastric contractions.  In patients with urinary retention, urinary reflux may occur if the sphincter fails to relax when the bladder is contracted by cholinergic stimulation.  The reflux of urine from the bladder can cause infection in the kidneys and upper urinary tract if bacteriuria is present.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4530, 0, 'Bethanechol', 'Hyperthyroidism', 'The use of cholinergic agents may be contraindicated in patients with hyperthyroidism.  Atrial fibrillation has occurred in hyperthyroid patients administered a cholinergic agonist.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4531, 0, 'Bethanechol', 'Parkinsonian Disorders', 'The use of cholinergic agonists may be contraindicated in patients with parkinsonism.  Cholinergic agonists directly stimulates the parasympathetic nervous system inducing acetylcholinergic effects.  Symptoms of Parkinson''s disease may be exacerbated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4532, 0, 'Bethanechol', 'Epilepsy', 'The use of cholinergic agonists may be contraindicated in patients with seizure disorders.  Cholinomimetics have been associated with convulsions.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4533, 0, 'Acetylsalicylic acid', 'Blood Coagulation Disorders', 'The use of aspirin is contraindicated in patients with significant active bleeding or hemorrhagic disorders such as hemophilia, von Willebrand''s disease, or telangiectasia.  Aspirin interferes with coagulation by irreversibly inhibiting platelet aggregation and prolonging bleeding time.  The non-aceylated salicylates (i.e. salicylate salts such as sodium or magnesium salicylate) do not demonstrate these effects and may be appropriate substitutions in these patients.  However, all salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially aspirin, should be administered with extreme caution in patients with hypoprothrombinemia, vitamin K deficiency, thrombocytopenia, thrombotic thrombocytopenic purpura, severe hepatic impairment, or anticoagulant use.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4534, 0, 'Acetylsalicylic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4535, 0, 'Acetylsalicylic acid', 'Peptic Ulcer', 'Salicylates, particularly aspirin, can cause dose-related gastrointestinal bleeding and mucosal damage, which may occur independently of each other.  Occult, often asymptomatic GI blood loss is quite common with usual dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  In contrast, major upper GI bleeding rarely occurs except in patients with active peptic ulcers or recent GI bleeding.  However, these patients generally do not experience greater occult blood loss than healthy patients following small doses of aspirin.  Mucosal damage associated with the use of salicylates may lead to development of peptic ulcers with or without bleeding, reactivation of latent ulcers, and ulcer perforation.  Therapy with salicylates and related agents such as salicylamide should be considered and administered cautiously in patients with a history of GI disease or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of these drugs and seem to tolerate ulceration and bleeding less well than other individuals.  Extreme caution and thorough assessment of risks and benefits are warranted in patients with active or recent GI bleeding or lesions.  Whenever possible, especially if prolonged use is anticipated, treatment with non-ulcerogenic agents should be attempted first.  If salicylates are used, close monitoring for toxicity is recommended.  Some adverse GI effects may be minimized by administration with high dosages of antacids, use of enteric-coated or extended-release formulations, and/or concurrent use of a histamine H2-receptor antagonist or a cytoprotective agent such as misoprostol.  Patients with active peptic ulceration or GI bleeding treated with salicylates should generally be administered a concomitant anti-ulcer regimen.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4536, 0, 'Acetylsalicylic acid', 'Kidney Diseases', 'Salicylate and its metabolites are eliminated almost entirely by the kidney.  Therapy with salicylate drugs should be administered cautiously in patients with renal impairment, especially if it is severe.  Reduced dosages may be necessary to avoid drug accumulation.  Clinical monitoring of renal function is recommended during prolonged therapy, since the use of salicylate drugs has rarely been associated with renal toxicities, including elevations in serum creatinine, renal papillary necrosis, and acute tubular necrosis with renal failure.  Most of the data have been derived from experience with aspirin but may apply to other salicylates as well.  In patients with impaired renal function, aspirin has caused reversible and sometimes marked decreases in renal blood flow and glomerular filtration rate.  Adverse renal effects have usually reversed rapidly following withdrawal of aspirin therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4537, 0, 'Acetylsalicylic acid', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4538, 0, 'Acetylsalicylic acid', 'Anemia', 'Occult, often asymptomatic GI blood loss occurs quite frequently with the use of normal dosages of aspirin and stems from the drug''s local effect on the GI mucosa.  During chronic therapy, this type of bleeding may occasionally produce iron deficiency anemia.  Other salicylates reportedly cause little or no GI blood loss at usual dosages, but may do so at high dosages.  Prolonged therapy with salicylates, particularly aspirin, should be administered cautiously in patients with or predisposed to anemia.  Periodic monitoring of hematocrit is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4539, 0, 'Acetylsalicylic acid', 'Diseases requiring dialysis', 'Salicylate and its metabolites are readily removed by hemodialysis and, to a lesser extent, by peritoneal dialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4540, 0, 'Acetylsalicylic acid', 'Glucosephosphate Dehydrogenase Deficiency', 'Salicylates, particularly aspirin, may cause or aggravate hemolysis in patients with pyruvate kinase or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  However, this effect has not been clearly established.  Until more data are available, therapy with salicylates should be administered cautiously in patients with G-6-PD deficiency.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4541, 0, 'Acetylsalicylic acid', 'Liver Diseases', 'The use of salicylates has occasionally been associated with acute, reversible hepatotoxicity, primarily manifested as elevations of serum transaminases, alkaline phosphatase and/or, rarely, bilirubin.  Hepatic injury consistent with chronic active hepatitis has also been reported in a few patients, which resulted rarely in encephalopathy or death.  Salicylate-induced hepatotoxicity appears to be dependent on serum salicylate concentration (> 25 mg/dL) and has occurred most frequently in patients with juvenile arthritis, active systemic lupus erythematosus, rheumatic fever, or preexisting hepatic impairment.  Therapy with salicylates, particularly when given in high dosages, should be administered cautiously in these patients, and periodic monitoring of liver function is recommended.  The same precautions should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.  A dosage reduction may be necessary if liver function abnormalities develop and serum salicylate concentration exceeds 25 mg/dL, although serum transaminase elevations may sometimes be transient and return to pretreatment values despite continued therapy without dosage adjustment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4542, 0, 'Betrixaban', 'Hemorrhage', 'The use of betrixaban is contraindicated in patients with active pathological bleeding.  Care and close monitoring is recommended when using this agent in patients who are receiving neuraxial anesthesia or undergoing spinal puncture as epidural or spinal hematomas may occur.  Consider risk of using this agent when scheduling patients for spinal procedures.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4543, 0, 'Betrixaban', 'Liver Diseases', 'The use of betrixaban is not recommended in patients with hepatic impairment as these patients may have intrinsic coagulation abnormalities.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4544, 0, 'Betrixaban', 'Kidney Diseases', 'Patients with severe renal impairment (CrCl >= 15 to < 30 mL/min computed by Cockcroft-Gault using actual body weight) may have an increased risk of bleeding events.  It is recommended to reduce the betrixaban dose in patients with severe renal impairment.  Monitor patients closely and promptly evaluate any signs or symptoms of blood loss in these patients.  No dose adjustment is needed for mild or moderate renal impairment (CrCl > 30 mL/min, computed by Cockcroft-Gault using actual body weight).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4545, 0, 'Betrixaban', 'Antiphospholipid Syndrome', 'Direct acting oral anticoagulants including factor Xa inhibitors and some thrombin inhibitors as dabigatran, are not recommended for use in patients with antiphospholipid syndrome (APS).  Treatment with these drugs has been associated with increased rates of recurrent thrombotic events, especially in patients with triple positive APS.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4546, 0, 'Abaloparatide', 'Hyperparathyroidism', 'Patients known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, should not be treated with parathyroid hormone and its analogs because of the risk of exacerbating hypercalcemia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4547, 0, 'Abaloparatide', 'Neoplasms', 'Parathyroid hormone and its analogs should not be used in patients who are at increased baseline risk for osteosarcoma.  These agents should only be used if the potential benefits are considered to outweigh the potential risks.  Monitor these patients according to clinical guidelines.  Patients with bone metastases or a history of skeletal malignancies should not be treated with these agents.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4548, 0, 'Abaloparatide', 'Urolithiasis', 'No dosage adjustment is required for patients with mild, moderate, or severe renal impairment.  Patients with severe renal impairment may have increased abaloparatide exposure that may increase the risk of adverse reactions; therefore, monitor for adverse reactions.  Abaloparatide may exacerbate urolithiasis in patients with active or a history of urolithiasis.  If active urolithiasis or preexisting hypercalciuria is suspected, measurement of urinary calcium excretion should be considered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4549, 0, 'Bicalutamide', 'Liver Diseases', 'Bicalutamide is extensively metabolized by the liver and its metabolism may be altered and/or delayed in patients with moderate to severe hepatic impairment.  Therapy with bicalutamide should be administered cautiously in patients with moderate to severe hepatic impairment.  Additionally there have been postmarketing reports of death or hospitalization due to severe liver injury (hepatic failure) in association with bicalutamide, so extra caution is advised in patients with hepatic impairment.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Clinical monitoring of hepatic function is recommended.  Although hepatic abnormalities such as elevated liver transaminase levels and jaundice are usually reversible, bicalutamide therapy should be discontinued if transaminase levels exceed two times the upper normal limits.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4550, 0, 'Betaxolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4551, 0, 'Betaxolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4552, 0, 'Betaxolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4553, 0, 'Betaxolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4554, 0, 'Betaxolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4555, 0, 'Betaxolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4556, 0, 'Betaxolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4557, 0, 'Betaxolol (ophthalmic)', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4558, 0, 'Betaxolol (ophthalmic)', 'Myasthenia Gravis', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the nervous and musculoskeletal systems, beta blockade may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4559, 0, 'Acitretin', 'Hyperlipidemias', 'Acitretin is contraindicated in patients with chronic abnormally elevated blood lipid values.  It is recommended to evaluate lipid status in patients before initiation of therapy and periodically until the lipid response to the drug is established.  Care should be taken in subjects with an increased tendency to develop hypertriglyceridemia included those with disturbances of lipid metabolism, obesity, or a familial history of these conditions.  Serum lipids must be more closely monitored in high-risk patients and during long-term treatment with acitretin.  Dietary modifications, reduction in dose of acitretin, or drug therapy should be employed to control significant elevations of triglycerides, and if hypertriglyceridemia and low HDL levels persist, discontinuation of acitretin should be considered.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4560, 0, 'Acitretin', 'Liver Diseases', 'The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis.  Therapy with acitretin is contraindicated in patients with severely impaired liver function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4561, 0, 'Acitretin', 'Kidney Diseases', 'The use of acitretin has been associated with significant lower plasma concentrations in patients with end-stage renal failure.  Therapy with acitretin is contraindicated in patients with severely impaired kidney function.  It is recommended to monitor renal function as per clinical guidelines.  Acitretin is not removed by hemodialysis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4562, 0, 'Acitretin', 'Intracranial Hypertension', 'The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension).  Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances.  Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist.  If the diagnosis is confirmed, the retinoid should be discontinued permanently.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4563, 0, 'Acitretin', 'Mental Disorders', 'The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation.  Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression.  In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4564, 0, 'Acitretin', 'Alcoholism', 'Like other retinoids, acitretin is a teratogen.  The concurrent use of alcohol and acitretin has been associated with the formation of etretinate, a related retinoid drug with a considerably longer half-life (mean: 120 days vs. 49 hours).  Alcohol should be avoided during acitretin therapy and for two months after completion of therapy in female patients of child-bearing age, since it may prolong the duration of teratogenic potential of the drug.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4565, 0, 'Acitretin', 'Diabetes Mellitus', 'The use of acitretin may adversely affect blood sugar levels and result in problems with blood sugar control.  In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.  It is recommended to monitor blood sugar levels very closely in diabetic patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4566, 0, 'Acitretin', 'Toxic Optic Neuropathy', 'Ophthalmologic manifestations have been reported with the use of acitretin.  It is recommended that any patient treated with acitretin who is experiencing visual difficulties should discontinue the drug and undergo ophthalmologic evaluation.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4567, 0, 'Bexarotene', 'Cataract', 'The use of bexarotene may cause new cataracts or worsening of previous cataracts.  It is recommended to monitor closely for the development of any visual difficulties and to have an appropriate ophthalmologic evaluation.  Exercise caution when using this agent in patients with a history of cataracts.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4568, 0, 'Bexarotene', 'Diabetes Mellitus', 'The use of bexarotene may cause hypoglycemia in diabetic patients.  It is recommended to measure baseline blood glucose levels and to keep monitoring them closely during treatment.  Exercise caution when using this agent in diabetic patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4569, 0, 'Bexarotene', 'Hyperlipidemias', 'The use of bexarotene may cause elevations in lipids.  It is recommended to monitor lipid levels closely and to obtain a fasting blood lipid reading at baseline and weekly until lipid response to the drug is established.  Exercise caution when using this agent in patients with hyperlipidemia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4570, 0, 'Bexarotene', 'Hypothyroidism', 'The use of bexarotene may cause hypothyroidism.  It is recommended to consider thyroid hormone supplementation in patients with hypothyroidism, to obtain baseline thyroid function tests, and to closely monitor patients during treatment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4571, 0, 'Bexarotene', 'Liver Diseases', 'In vitro studies suggest that cytochrome P450 3A4 is the major cytochrome P450 responsible for formation of the oxidative metabolites and that the oxidative metabolites may be glucuronidated.  It is recommended to monitor for signs of toxicity due to increased drug exposure if bexarotene is used in patients with hepatic impairment as these patients are expected to have a decreased drug clearance.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4572, 0, 'Bexarotene', 'Neutropenia', 'The use of bexarotene causes neutropenia.  Neutropenia is reversible after dose reduction or discontinuation of treatment.  Care should be exercised in patients at risk.  It is recommended to obtain complete blood counts at baseline and periodically during treatment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4573, 0, 'Bexarotene', 'Pancreatitis', 'Pancreatitis, including a fatal case, has occurred in patients receiving bexarotene.  It is recommended to monitor for pancreatitis and to interrupt treatment if pancreatitis is suspected.  Close monitoring is recommended in patients who have risk factors for pancreatitis, such as high alcohol consumption, uncontrolled diabetes or hyperlipidemia, and prior pancreatitis, as these patients might be at greater risk.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4574, 0, 'Ziconotide', 'Infections', 'The use of ziconotide is contraindicated in patients with any other concomitant treatment or medical condition that would render intrathecal administration hazardous.  Contraindications to the use of intrathecal analgesia include the presence of infection at the microinfusion injection site, uncontrolled bleeding diathesis, and spinal canal obstruction that impairs circulation of cerebrospinal fluid.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4575, 0, 'Ziconotide', 'Psychotic Disorders', 'The use of ziconotide is contraindicated in patients with a preexisting history of psychosis.  Severe psychiatric symptoms and neurological impairment may occur during therapy with ziconotide.  It is recommended to monitor all patients for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness during treatment with ziconotide.  Discontinue therapy with ziconotide in the event of serious neurological or psychiatric signs or symptoms.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4576, 0, 'Botulinum toxin type A', 'Lactose Intolerance', 'Dysport (brand of abobotulinumtoxinA) may contain trace amounts of cow''s milk protein.  Patients known to be allergic to cow''s milk protein should not be treated with this product.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4577, 0, 'Botulinum toxin type A', 'Neuromuscular Diseases', 'Treatment with botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, daxibotulinumtoxinA and others can result in swallowing and breathing difficulties and in general increased neuromuscular compromise.  Deaths due to severe dysphagia or respiratory failure have been reported after treatment with botulinum toxin.  Care should be exercised with using these products in patients with pre- existing swallowing or respiratory disorders or peripheral motor neuropathic diseases or neuromuscular disorders (e.g., myasthenia gravis, amyotrophic lateral sclerosis), as they may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia and respiratory compromise.  Patients treated with botulinum toxin may require immediate medical attention should they develop these complications.  Caution is advised.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4578, 0, 'Botulinum toxin type A', 'Infections', 'Botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, and others should not be used in the presence of infection at the proposed injection site(s) as it could lead to severe local or disseminated infection(s).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4579, 0, 'Botulinum toxin type A', 'Urinary Tract Infections', 'Botox (brand of onabotulinumtoxinA), a botulinum toxin product for the treatment of overactive bladder or detrusor overactivity associated with a neurologic condition should not be used in patients who have a urinary tract infection, in patients with urinary retention and in patients with post-void residual urine volume >200 mL, who are not routinely performing clean intermittent self-catheterization.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4580, 0, 'Botulinum toxin type A', 'Glaucoma, Angle-Closure', 'Xeomin (brand of incobotulinumtoxinA), a botulinum toxin product for the treatment of blepharospasm should be used with caution in patients at risk of developing narrow angle glaucoma.  The anticholinergic effects of botulinum toxin products can reduce blinking and lead to corneal exposure, persistent epithelial defect and corneal ulceration, especially in patients with VII nerve disorders.  To prevent ectropion, it is recommended that botulinum toxin products should not be injected into the medial lower eyelid area.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4581, 0, 'Bisoprolol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4582, 0, 'Bisoprolol', 'Shock, Cardiogenic', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with hypotension or cardiogenic shock.  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to further depress cardiac output and blood pressure, which can be detrimental in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4583, 0, 'Bisoprolol', 'Heart Failure', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with overt congestive heart failure (CHF).  Sympathetic stimulation may be important in maintaining the hemodynamic function in these patients, thus beta-blockade can worsen the heart failure.  However, therapy with beta-blockers may be beneficial and can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Carvedilol, specifically, is indicated for use with these agents in the treatment of mild to severe heart failure of ischemic or cardiomyopathic origin.  There is also increasing evidence that the addition of a beta-blocker to standard therapy can improve morbidity and mortality in patients with advanced heart failure, although it is uncertain whether effectiveness varies significantly with the different agents.  Data from one meta-analysis study suggest a greater reduction of mortality risk for nonselective beta-blockers than for beta-1 selective agents.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4584, 0, 'Bisoprolol', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since cardioselectivity is not absolute, larger doses of beta-1 selective agents may demonstrate these effects as well.  Therapy with beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4585, 0, 'Bisoprolol', 'Diseases requiring hemodialysis', 'Therapy with beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in patients requiring hemodialysis.  When given after dialysis, hemodynamic stability should be established prior to drug administration to avoid marked falls in blood pressure.  The hemodynamic status should be closely monitored before and after the dose.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4586, 0, 'Bisoprolol', 'Hypersensitivity', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4587, 0, 'Bisoprolol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4588, 0, 'Bisoprolol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4589, 0, 'Bisoprolol', 'Liver Diseases', 'Bisoprolol is eliminated by both the kidney and liver.  Patients with renal and/or liver disease may be at greater risk for adverse effects from bisoprolol due to decreased drug clearance.  Initial dosage adjustments and cautious titration are recommended in patients with a creatinine clearance below 40 mL/min and/or liver disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4590, 0, 'Bisoprolol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4591, 0, 'Bisoprolol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4592, 0, 'Bisoprolol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4593, 0, 'Bisoprolol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4594, 0, 'Bisoprolol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4595, 0, 'Bisoprolol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4596, 0, 'Bisoprolol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4597, 0, 'Bisoprolol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4598, 0, 'Bisoprolol', 'Asthma', 'Patients with bronchospastic disease, should, in general, not receive beta blockers, including cardioselective beta-blockers.  Because of the relative beta-1 selectivity, cardioselective beta-blockers may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment.  Because beta-1 selectivity is not absolute, the lowest possible dose of these agents should be used.  Consider administering in smaller doses to avoid the higher plasma levels associated with the longer dosing intervals.  If dosage must be increased, dividing the dose should be considered to achieve lower peak blood levels.  It is recommended to have bronchodilators, including beta-2 agonists, readily available or administered concomitantly if necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4599, 0, 'Boceprevir', 'Pancytopenia', 'Anemia, neutropenia and thrombocytopenia has been reported with the use of boceprevir.  Boceprevir is always administered with peginterferon alfa and ribavirin which are also associated with pancytopenia.  The addition of boceprevir has shown an additional decrease in hemoglobin and blood cell counts.  Caution should be used in patients with preexisting anemia, neutropenia or thrombocytopenia.  A complete blood count should be obtained pretreatment, and then during treatment at weeks 2, 4, 8, and 12.  Patients should be monitored closely.  Refer to the prescribing information for peginterferon alfa and ribavirin for additional information regarding dose reduction or discontinuation based on laboratory parameters.  If ribavirin and peginterferon alfa need to be discontinued, boceprevir should be discontinued as well.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4600, 0, 'Aclidinium', 'Milk Hypersensitivity', 'Some inhaled anticholinergic bronchodilators such as aclidinium and umeclidinium are contraindicated in patients with severe hypersensitivity to milk proteins.  There have been reports of anaphylactic reactions on these patients after inhalation of other powder products containing lactose, therefore patients with severe milk protein allergy should not use these products.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4601, 0, 'Aclidinium', 'Liver Failure', 'The manufacturers report that the effects of hepatic impairment on the pharmacokinetics of aclidinium have not been studied.  Caution is advised if used on these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4602, 0, 'Aclidinium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4603, 0, 'Botulinum toxin type B', 'Infections', 'The use of rimabotulinumtoxinB is contraindicated for use in patients with infection at the proposed injection site.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4604, 0, 'Botulinum toxin type B', 'Deglutition Disorders', 'Treatment with rimabotulinumtoxinB can result in swallowing or breathing difficulties.  Patients with preexisting-existing swallowing or breathing difficulties may be more susceptible to these complications.  Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin.  Dysphagia may persist for several months and require use of a feeding tube to maintain adequate nutrition and hydration.  Treatment of cervical dystonia with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation, which may result in a critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles.  There have been postmarketing reports of serious breathing difficulties, including respiratory failure, in cervical dystonia patients.  Patients treated with rimabotulinumtoxinB may require immediate medical attention should they develop problems with swallowing, speech or respiratory disorders.  These reactions can occur within hours to weeks after injection.  Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given rimabotulinumtoxinB, as they may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of rimabotulinumtoxinB.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4605, 0, 'Bisacodyl', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4606, 0, 'Bisacodyl', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4607, 0, 'Bisacodyl', 'Appendicitis', 'The use of stimulant laxatives is contraindicated in patients with or who may have acute surgical abdomen or appendicitis.  These patients may be candidates for emergency surgery.  Stimulant laxatives should also not be administered to patients with abdominal pain, particularly if the cause has not been determined.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4608, 0, 'Bisacodyl', 'Rectal Diseases', 'The use of stimulant laxatives is contraindicated in patients with anal or rectal fissures.  These preparations may cause irritation, burning sensation, and proctitis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4609, 0, 'Bortezomib', 'Cardiotoxicity', 'Acute development or exacerbation of congestive heart failure and new onset of decreased left ventricular ejection fraction have occurred during treatment with bortezomib, including in patients with no risk factors.  Patients with risk factors for, or existing heart disease should be closely monitored.  There have also been isolated cases of QT interval prolongation but causality has not been established.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4610, 0, 'Bortezomib', 'Diabetes Mellitus', 'Hypoglycemia and hyperglycemia was reported during clinical trials in diabetic patients in treatment with oral hypoglycemics and receiving bortezomib.  Patients on oral antidiabetic agents may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication when using bortezomib.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4611, 0, 'Bortezomib', 'Liver Diseases', 'Cases of acute liver failure and other hepatic reactions such as hepatitis, increases in liver enzymes, and hyperbilirubinemia have been reported in patients receiving bortezomib.  Monitoring is recommended and caution should be used when using bortezomib in patients with hepatic impairment.  The exposure of bortezomib is increased in patients with moderate and severe hepatic impairment, and starting dose should be reduced in those patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4612, 0, 'Bortezomib', 'Hypotension', 'There was an incidence of 8% of hypotension in patients receiving bortezomib therapy.  Caution should be used when treating patients with history of hypotension, syncope, dehydration, or taking antihypertensive medication.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4613, 0, 'Bortezomib', 'Peripheral Nervous System Diseases', 'Bortezomib can cause peripheral neuropathy that is predominantly sensory; however cases of severe sensory and motor peripheral neuropathy have been also reported.  Patients with preexisting symptoms (numbness, pain or burning feeling in hands or feet) may experience worsening symptoms during treatment.  Patients should be monitored for symptoms of neuropathy, and a dose adjustment might be required in those patients that experience them.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4614, 0, 'Bortezomib', 'Lung Diseases', 'There have been reports of Acute Respiratory Distress Syndrome (ARDS) and acute diffuse infiltrative pulmonary disease of unknown etiology in patients receiving bortezomib.  Additionally, there have been reports of pulmonary hypertension associated with bortezomib administration in the absence of left heart failure or significant pulmonary disease.  Treatment interruption should be considered in the event of new or worsening cardiopulmonary symptoms until a comprehensive diagnostic evaluation is conducted.  Caution should be exercised when using bortezomib in patients with cardiopulmonary pathologies.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4615, 0, 'Bosentan', 'Liver Failure', 'Endothelin receptor antagonists (ERAs) have been associated with aminotransferase elevations, hepatotoxicity, and cases of liver failure.  Hepatic function should be assessed before treatment initiation and closely monitored during treatment.  Therapy should be discontinued if aminotransferase elevations are accompanied by increases in bilirubin, or clinical symptoms of hepatotoxicity such as nausea, vomiting, fever, abdominal pain or jaundice.  Treatment should be avoided in patients with elevated aminotransferases at baseline as monitoring for hepatotoxicity may be more difficult.  In general, the use of ERAs is not recommended for patients with moderate to severe hepatic impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4616, 0, 'Bosentan', 'Anemia', 'Clinical studies have shown that most endothelin receptor antagonists decrease hemoglobin concentration and hematocrit levels.  There are some postmarketing reports of anemia cases which needed blood transfusion.  Hemoglobin and hematocrit levels should be measured prior to treatment initiation and should be monitored periodically thereafter.  Initiation of therapy is not recommended in patients with clinically significant anemia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4617, 0, 'Bosentan', 'Water-Electrolyte Imbalance', 'Peripheral edema and fluid retention are known clinical consequences of pulmonary hypertension and also known effects of endothelin receptor antagonists.  Caution and monitoring is recommended if these agents are used in patients with underlying left ventricular dysfunction or underlying heart failure, as they have an increased risk for developing significant fluid retention that may need treatment or require discontinuation.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4618, 0, 'Bretylium', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4619, 0, 'Bretylium', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4620, 0, 'Bretylium', 'Kidney Diseases', 'Bretylium is primarily eliminated by the kidney.  Approximately 77% of bretylium is excreted in the urine unchanged.  There are no known metabolites of bretylium.  The serum concentration of bretylium is increased and the half-life prolonged in patients with renal impairment.  Therapy with bretylium should be administered cautiously and the dosing interval increased in patients with compromised renal impairment.  Clinical monitoring of cardiac function (ECG) and renal function is recommended.  Bretylium is moderately removed during hemodialysis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4621, 0, 'Blinatumomab', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4622, 0, 'Blinatumomab', 'Cardiovascular Diseases', 'The use of monoclonal antibodies administered via IV infusion may cause serious infusion reactions, including bronchospasm, hypoxia, dyspnea, fluctuations in blood pressure, laryngeal edema and pulmonary edema.  Caution should be taken in patients with a history of cardiopulmonary disease as they may require additional post-infusion medications to manage respiratory complications.  It is recommended to administer required intravenous hydration and premedication with antihistamines, analgesics, and antipyretics before administration.  Monitor closely for signs and symptoms of infusion reactions during and for at least 4 hours following completion of each infusion in a setting where cardiopulmonary resuscitation medication and equipment are available.  Immediately interrupt or permanently discontinue treatment and institute supportive management for severe or prolonged infusion reactions as appropriate.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4623, 0, 'Blinatumomab', 'Tumor Lysis Syndrome', 'Tumor lysis syndrome (TLS) has occurred in patients receiving certain monoclonal antibodies.  Patients with high tumor burden and those with high circulating lymphocyte counts of greater than 25 X 10^9/L have a higher risk of developing TLS.  Consider tumor lysis prophylaxis prior to the infusion with anti-hyperuricemics and hydration beginning 12 to 24 hours prior to infusion.  It is recommended to correct electrolytes abnormalities, and monitor renal function in patients who develop TLS.  Monitor for signs and symptoms of TLS and temporary interruption or discontinuation of therapy might be required.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4624, 0, 'Blinatumomab', 'Liver Diseases', 'The use of blinatumomab has been associated with transient elevations in liver enzymes.  Care should be exercised when using this agent in patients with liver impairment.  It is recommended to monitor liver enzymes before the start of therapy and periodically as clinically appropriate.  Interrupt treatment if the transaminases levels rise to greater than 5 times the upper limit of normal or if bilirubin rises to more than 3 times the upper limit normal.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4625, 0, 'Blinatumomab', 'Nervous System Diseases', 'Serious neurological toxicity such as encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders have been reported with the use of blinatumomab therapy.  Monitor therapy closely if administered to patients with or predisposed to neurological impairment and interruption or discontinuation of therapy might be appropriate in some cases.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4626, 0, 'Blinatumomab', 'Neutropenia', 'The use of blinatumomab may cause life-threatening neutropenia, and febrile neutropenia.  It is recommended to monitor complete blood counts during the infusion.  Therapy interruption is recommended for prolonged neutropenia.  Care and close monitoring is recommended, in particular for any episodes of fever.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4627, 0, 'Blinatumomab', 'Pancreatitis', 'Fatal pancreatitis has been observed in patients treated with blinatumomab in combination with dexamethasone.  Care should be exercised when using blinatumomab in combination with dexamethasone in patients with pancreatic disorders.  Management of pancreatitis may require either temporary interruption or discontinuation of these agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4628, 0, 'Blinatumomab', 'Kidney Diseases', 'No formal pharmacokinetic studies of blinatumomab have been conducted in patients with renal impairment.  Pharmacokinetic analyses showed an approximately 2-fold difference in mean blinatumomab clearance values between patients with moderate renal impairment (CrCl ranging from 30 to 59 mL/min, N = 21) and normal renal function.  However, high interpatient variability was observed (CV% up to 96.8%), and clearance values in renal impaired patients were essentially within the range observed in patients with normal renal function.  Close monitoring is recommended in patients with severe renal impairment (CrCl less than 30 mL/min) or patients on hemodialysis as there is no information available.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4629, 0, 'Bremelanotide', 'Cardiovascular Diseases', 'Bremelanotide is contraindicated in patients who have uncontrolled hypertension or known cardiovascular disease, as it transiently increases blood pressure and reduces heart rate after each dose.  Before initiating bremelanotide, and periodically during treatment, consider the patient''s cardiovascular risk and ensure blood pressure is well-controlled.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4630, 0, 'Bremelanotide', 'Liver Failure', 'Bremelanotide has not been evaluated in patients with severe hepatic impairment and should be used with caution in these patients (Child-Pugh C; score 10-15), because they may have an increase in the incidence and severity of adverse reactions (e.g., nausea and vomiting).  No dosing adjustments are recommended for patients with mild to moderate (Child-Pugh A and B; score 5-9) hepatic impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4631, 0, 'Bremelanotide', 'Kidney Failure, Chronic', 'Use bremelanotide with caution in patients with severe (eGFR <30 mL/min/1.73 m2) renal impairment, because these patients may have an increase in the incidence and severity of adverse reactions (e.g., nausea and vomiting).  No dosing adjustments are recommended for patients with mild to moderate (eGFR 30-89 mL/min/1.73 m2) renal impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4632, 0, 'Brentuximab vedotin', 'Liver Diseases', 'The use of brentuximab vedotin should be avoided in patients with moderate or severe hepatic impairment.  Serious cases of hepatotoxicities have occurred in patients receiving this agent.  Patients with preexisting liver disease, and those with elevated baseline liver enzymes may be at an increased risk.  Monitor liver enzymes and bilirubin.  Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dose, or discontinuation of therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4633, 0, 'Brentuximab vedotin', 'Infections', 'Serious infections, including opportunistic infections have been reported with the use of brentuximab vedotin.  Monitor patients closely for the development of any infection during treatment with this agent.  JC virus infection resulting in progressive multifocal leukoencephalopathy (PML) has been reported in patients treated with this agent.  A diagnosis of PML should be considered in any patient presenting with new-onset of neurological manifestations and a consultation with a neurologist is recommended.  Hold therapy for any suspected case of PML and discontinue if a diagnosis of PML is confirmed.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4634, 0, 'Brentuximab vedotin', 'Kidney Diseases', 'The frequency of adverse reactions, including fatalities are increased in patients with severe renal impairment.  It is recommended to avoid the use of this agent in patients with severe renal impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4635, 0, 'Brentuximab vedotin', 'Tumor Lysis Syndrome', 'Tumor lysis syndrome (TLS) has occurred in patients receiving certain monoclonal antibodies.  Patients with high tumor burden and those with high circulating lymphocyte counts of greater than 25 X 10^9/L have a higher risk of developing TLS.  Consider tumor lysis prophylaxis prior to the infusion with anti-hyperuricemics and hydration beginning 12 to 24 hours prior to infusion.  It is recommended to correct electrolytes abnormalities, and monitor renal function in patients who develop TLS.  Monitor for signs and symptoms of TLS and temporary interruption or discontinuation of therapy might be required.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4636, 0, 'Brentuximab vedotin', 'Neutropenia', 'Hematological toxicities, including prolonged severe neutropenia, thrombocytopenia or anemia can occur with the use of brentuximab vedotin.  It is recommended to monitor patients for fever and if appropriate, dose delays, reduction, or discontinuation of treatment should be considered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4637, 0, 'Brentuximab vedotin', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy, predominantly sensory neuropathy has occurred in patients treated with brentuximab vedotin.  It is recommended to monitor patients for symptoms of neuropathy and in those experiencing new or worsening peripheral neuropathy.  It is recommended to delay, or change dosage, or discontinue treatment as appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4638, 0, 'Brentuximab vedotin', 'Lung Diseases', 'Cases of noninfectious pulmonary toxicity including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome (ARDS), some with fatal outcomes, have been reported with the use of brentuximab vedotin.  Care should be taken when using this agent in patients at risk of pulmonary events.  Hold dose in the event of new or worsening of pulmonary complications until symptoms improve.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4639, 0, 'Brentuximab vedotin', 'Digestive System Diseases', 'Cases of fatal and serious gastrointestinal complication have been reported with the use of brentuximab vedotin.  Care should be taken when using this agent in patients with a history of gastrointestinal complications, as its use can increase the risk of perforation.  Closely monitor for new or worsening of GI symptoms and treat according to clinical practices.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4640, 0, 'Biperiden', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4641, 0, 'Biperiden', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4642, 0, 'Biperiden', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4643, 0, 'Biperiden', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4644, 0, 'Biperiden', 'Tardive Dyskinesia', 'Anticholinergic agents and agents with secondary anticholinergic activity may aggravate tardive dyskinesia or induce previously suppressed symptoms.  Therapy with these agents should be avoided, if possible, or administered cautiously in patients with preexisting tardive dyskinesia, particularly in the elderly.  If tardive dyskinesia symptoms develop or worsen during treatment with an anticholinergic agent, prompt withdrawal of therapy will provide better chances of improving the condition.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4645, 0, 'Biperiden', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4646, 0, 'Biperiden', 'Heart Diseases', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously to patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization, ventricular tachycardia, and fibrillation associated with anticholinergics are rare.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4647, 0, 'Biperiden', 'Liver Diseases', 'The clearance of anticholinergics may be decreased in the presence of liver disease.  Therapy with anticholinergics should be administered cautiously and may require less frequent dosing to avoid adverse effects in patients with liver disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4648, 0, 'Biperiden', 'Hypertension', 'Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4649, 0, 'Biperiden', 'Hyperthyroidism', 'In general, agents with anticholinergic activity may exacerbate hyperthyroidism.  Therapy with anticholinergics should be administered cautiously in patients with hyperthyroidism.  Thyroid levels should be monitored if usage is prolonged.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4650, 0, 'Bosutinib', 'Cardiovascular Diseases', 'Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors.  If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention.  The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4651, 0, 'Bosutinib', 'Water-Electrolyte Imbalance', 'Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.  Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure.  Monitor and manage patients using standards of care.  Interrupt, reduce dose or discontinue therapy as necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4652, 0, 'Bosutinib', 'Bone Marrow Failure Disorders', 'Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors.  Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated.  To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4653, 0, 'Bosutinib', 'Dehydration', 'Adequate hydration might be necessary during therapy with bosutinib as diarrhea, nausea, vomiting, and abdominal pain occur with treatment.  Monitor and manage patients using standards of care, including antidiarrheals, antiemetics, and fluid replacement.  To manage gastrointestinal toxicity, withhold, dose reduce, or discontinue bosutinib as necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4654, 0, 'Bosutinib', 'Liver Diseases', 'Bosutinib is primarily metabolized by the CYP 450 3A4.  Therapy with bosutinib should be administered cautiously in patients with hepatic impairment and the starting dose should be 200 mg daily in patients with baseline hepatic impairment.  The manufacturer recommends performing hepatic enzyme tests monthly for the first three months of bosutinib treatment and as clinically indicated.  In patients with transaminase elevations, monitor liver enzymes more frequently.  Withhold, reduce dose, or discontinue bosutinib as necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4655, 0, 'Bosutinib', 'Kidney Diseases', 'An on-treatment decline in estimated glomerular filtration rate (eGFR) has occurred in patients treated with bosutinib.  The manufacturer recommends reducing the bosutinib starting dose in patients with severe (CrCl) less than 30 mL/min) or moderate (CrCl 30 to 50 mL/min) renal impairment at baseline.  Consider dose adjustment in patients with baseline and treatment emergent renal impairment.  It is recommended to monitor patients for renal function at baseline and during therapy with bosutinib, with particular attention to those patients who have preexisting renal impairment or risk factors for renal dysfunction.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4656, 0, 'Binimetinib', 'Cardiomyopathies', 'Cardiomyopathy, manifesting as left ventricular dysfunction associated with symptomatic or asymptomatic decreases in ejection fraction, has been reported in patients treated with binimetinib in combination with encorafenib.  The median time to first occurrence of left ventricular dysfunction (any grade) in patients receiving treatment was 3.6 months (range 0 to 21 months).  Cardiomyopathy resolved in 87% of the patients.  Ejection fraction should be assessed by echocardiogram or MUGA scan prior to initiating treatment, one month after initiating treatment, and then every 2 to 3 months during treatment.  The safety of this therapy has not been established in patients with a baseline ejection fraction that is either below 50% or below the institutional lower limit of normal (LLN).  Patients with cardiovascular risk factors should be monitored closely when treated with binimetinib.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4657, 0, 'Binimetinib', 'Hepatic Insufficiency', 'Binimetinib concentrations may increase in patients with moderate or severe hepatic impairment.  Reduce the dose of binimetinib for patients with moderate (total bilirubin > 1.5 and = 3  ULN and any AST) or severe (total bilirubin levels > 3  ULN and any AST) hepatic impairment.  Dose adjustment is not recommended in patients with mild hepatic impairment (total bilirubin > 1 and = 1.5  ULN and any AST or total bilirubin = ULN and AST > ULN).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4658, 0, 'Binimetinib', 'Retinal Diseases', 'Retinal vein occlusion (RVO) is a known class- related adverse reaction of MEK inhibitors and may occur in patients treated with binimetinib in combination with encorafenib.  The safety of binimetinib has not been established in patients with a history of RVO or current risk factors for RVO including uncontrolled glaucoma or a history of hyperviscosity or hypercoagulability syndromes.  An ophthalmologic evaluation should be performed for patient reporting acute vision loss or other visual disturbance within 24 hours.  Treatment should be discontinued in patients with documented RVO.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4659, 0, 'Bismuth subsalicylate', 'Reye Syndrome', 'The use of salicylates, primarily aspirin, in children with varicella infections or influenza-like illnesses has been associated with an increased risk of Reye''s syndrome.  Although a causal relationship has not been established, the majority of evidence to date seems to support the association.  Most authorities, including the American Academy of Pediatrics Committee on Infectious Diseases, recommend avoiding the use of salicylates in children and teenagers with known or suspected varicella or influenza and during presumed outbreaks of influenza.  If antipyretic or analgesic therapy is indicated under these circumstances, acetaminophen may be an appropriate alternative.  The same precautions should also be observed with related agents such as salicylamide or diflunisal because of their structural and pharmacological similarities to salicylate.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4660, 0, 'Bismuth subsalicylate', 'Blood Coagulation Disorders', 'All salicylates can interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X.  At usual recommended dosages, a slight increase in prothrombin time (PT) may occur.  Therapy with salicylates, especially if given in high dosages, should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  The same precaution should also be observed with the use of related agents such as salicylamide because of their structural and pharmacological similarities to salicylate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4661, 0, 'Bleomycin', 'Pulmonary Fibrosis', 'Pulmonary pneumonitis occurs in 10% of patients during bleomycin therapy and 1% progress to pulmonary fibrosis and death.  Although pulmonary toxicity is age and dose related, occurring primarily in patients over 70 years of age and in those receiving a total dose > 400 units, it has occurred in younger patients at a lower dose.  Extreme caution should be exercised when administering bleomycin in patients with compromised pulmonary function.  Patients should be instructed to immediately report symptoms of dyspnea, cough, or congestion.  Close clinical monitoring of pulmonary function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4662, 0, 'Bleomycin', 'Kidney Diseases', 'Bleomycin is primarily eliminated by the kidney.  Approximately 60% to 70% of bleomycin is excreted in the urine as active drug.  Moderate renal failure reduces elimination to < 20% of the drug.  Extreme caution should be exercised when administering bleomycin in patients with existing or predisposition to significantly compromised renal function.  Close clinical monitoring of renal function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4663, 0, 'Bleomycin', 'Hepatic Insufficiency', 'The effect of hepatic insufficiency on the pharmacokinetics of bleomycin has not been evaluated.  However, hepatic toxicity, beginning as a deterioration in liver function tests, has been reported.  These toxicities may occur at any time after initiation of therapy.  Caution and monitoring is advised if bleomycin is used in patients with liver impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4664, 0, 'Brexanolone', 'Kidney Diseases', 'The effect of end stage renal disease (ESRD, eGFR < 15 mL/minute/1.73 m2) on brexanolone pharmacokinetics is unknown, and its use should be avoided in these patients because of the potential accumulation of the solubilizing agent, betadex sulfobutyl ether sodium.  No dosage adjustment is recommended in patients with mild (eGFR 60 to 89 mL/minute/1.73 m2), moderate (eGFR 30 to 59 mL/minute/1.73 m2) or severe (eGFR 15 to 29 mL/minute/1.73 m2) renal impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4665, 0, 'Brexanolone', 'Depressive Disorder', 'A placebo-controlled trial showed that patients with major depressive disorder (MDD) had a higher incidence of suicidal thoughts and behaviors when treated with brexanolone.  Consider changing the therapeutic regimen, including discontinuing brexanolone, in patients whose depression becomes worse or who experience emergent suicidal thoughts and behaviors.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4666, 0, 'Brexpiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4667, 0, 'Brexpiprazole', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4668, 0, 'Brexpiprazole', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4669, 0, 'Brexpiprazole', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4670, 0, 'Brexpiprazole', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4671, 0, 'Brexpiprazole', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4672, 0, 'Brexpiprazole', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4673, 0, 'Brexpiprazole', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4674, 0, 'Brexpiprazole', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4675, 0, 'Brexpiprazole', 'Kidney Diseases', 'Therapy with some atypical antipsychotic agents should be administered cautiously in patients with renal impairment and the dosage should be reduced accordingly.  These agents are not recommended in patients with severe renal impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4676, 0, 'Brexpiprazole', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4677, 0, 'Brexpiprazole', 'Hepatic Insufficiency', 'Brexpiprazole is primarily metabolized by the liver.  It is recommended to reduce the dose of brexpiprazole in patients with moderate to severe hepatic impairment (Child-Pugh score greater than or equal to 7) as these patients might have a higher exposure to brexpiprazole than patients with normal hepatic function.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4678, 0, 'Brexpiprazole', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4679, 0, 'Brexpiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4680, 0, 'Bivalirudin', 'Hemorrhage', 'The use of thrombin inhibitors is contraindicated in the presence of active major bleeding.  Additionally, these drugs should be used with caution in patients with disease states associated with an increased risk of bleeding.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4681, 0, 'Bivalirudin', 'Kidney Diseases', 'Clinical studies showed that the clearance of bivalirudin is reduced approximately 20% with moderate and severe renal impairment and is reduced about 80% in dialysis-dependent patients.  The infusion dose of bivalirudin may need to be reduced, and anticoagulant status monitored in patients with renal impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4682, 0, 'Brigatinib', 'Liver Diseases', 'Following a single dose of 90 mg, unbound brigatinib systemic exposure was 37% higher in subjects with severe hepatic impairment (Child-Pugh C) compared to subjects with normal hepatic function.  It is recommended to reduce the dose by approximately 40% (i.e., from 180 mg to 120 mg, 120 mg to 90 mg, or from 90 mg to 60 mg) in these patients.  No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A) or moderate hepatic impairment (Child-Pugh B).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4683, 0, 'Brigatinib', 'Lung Diseases', 'Severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis have occurred with the use of brigatinib.  It is recommended to monitor for new or worsening respiratory symptoms (e.g., dyspnea, cough, etc.), particularly during the first week of initiating this drug.  Withhold brigatinib in any patient with new or worsening respiratory symptoms, and promptly evaluate for ILD/pneumonitis or other causes of respiratory symptoms (e.g., pulmonary embolism, tumor progression, and infectious pneumonia).  Dose modifications or permanent discontinuation may be necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4684, 0, 'Brigatinib', 'Kidney Diseases', 'Following a single dose of 90 mg, unbound brigatinib systemic exposure was 86% higher in subjects with severe renal impairment [creatinine clearance (CrCl) 15 to 29 mL/min] compared to subjects with normal renal function.  It is recommended to reduce dose by approximately 50% (i.e., from 180 mg to 90 mg, or from 90 mg to 60 mg) in these patients.  No dose adjustment is recommended for patients with mild or moderate renal impairment [creatinine clearance (CrCl) 30 to 89 mL/min].', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4685, 0, 'Brinzolamide (ophthalmic)', 'Hematologic Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia,  leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Therapy with topical sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4686, 0, 'Brinzolamide (ophthalmic)', 'Hypersensitivity, Immediate', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with topical sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4687, 0, 'Brinzolamide (ophthalmic)', 'Porphyrias', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Therapy with topical sulfonamides should be administered cautiously in patients with porphyria, since these drugs can precipitate an acute attack.  The use of oral sulfonamides is considered contraindicated in patients with porphyria.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4688, 0, 'Brinzolamide (ophthalmic)', 'Crystalluria', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with crystalluria due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4689, 0, 'Brinzolamide (ophthalmic)', 'Liver Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with topical sulfonamides should be administered cautiously in patients with liver disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4690, 0, 'Brinzolamide (ophthalmic)', 'Kidney Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).  Some manufacturers of topical sulfonamide products do not recommend their use in patients with impaired renal function.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4691, 0, 'Brinzolamide (ophthalmic)', 'Urethral Obstruction', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides are excreted and concentrated in the urine.  Therapy with topical sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4692, 0, 'Brimonidine (ophthalmic)', 'Cardiovascular Diseases', 'Topically applied alpha-2 adrenergic receptor agonists are systemically absorbed, with the potential for producing rare but clinically significant systemic effects.  In the central nervous system, alpha adrenergic stimulation causes an inhibition of sympathetic vasomotor centers, resulting in decreased peripheral resistance and bradycardia.  While the commercially available agents in the U.S. (apraclonidine and brimonidine) are hydrophilic and do not readily distribute across the ocular-blood barrier into the CNS, prolonged use may increase the risk of systemic effects.  There have been occasional reports of bradycardia, chest heaviness or burning, palpitation, reduced blood pressure, and orthostatic hypotension when apraclonidine 1% was administered once or twice a day for 4 weeks to individuals not undergoing laser surgery.  Therapy with ophthalmic alpha-2 adrenergic agents should be administered cautiously in patients with severe, uncontrolled cardiovascular disease, including hypertension, coronary or cerebrovascular insufficiency, recent myocardial infarction, chronic renal failure, Raynaud''s disease, thromboangiitis obliterans, and a predisposition for orthostatic hypotension.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4693, 0, 'Brimonidine (ophthalmic)', 'Depressive Disorder', 'Topically applied alpha-2 adrenergic receptor agonists are systemically absorbed, with the potential for producing rare but clinically significant systemic effects.  Depression has infrequently been associated with the ocular use of these drugs due to their inhibiting effect on the sympathetic nervous system.  Depressed patients should be monitored for exacerbation of their condition during therapy with ophthalmic alpha-2 adrenergic agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4694, 0, 'Brimonidine (ophthalmic)', 'Liver Failure', 'Topically applied alpha-2 adrenergic receptor agonists are systemically absorbed, with the potential for producing rare but clinically significant systemic effects.  There are limited data concerning the pharmacokinetic disposition or the clinical use of these drugs in patients with renal and/or liver disease.  Therapy with ophthalmic alpha-2 adrenergic agents should be administered cautiously in patients with significantly impaired renal or hepatic function.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4695, 0, 'Budesonide (nasal)', 'Hepatic Insufficiency', 'Formal pharmacokinetic studies using budesonide inhalation suspension have not been conducted in patients with hepatic impairment.  However, since budesonide is predominantly cleared by hepatic metabolism, impairment of liver function may lead to accumulation of budesonide in plasma.  Patients with hepatic disease should be monitored closely.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4696, 0, 'Budesonide (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4697, 0, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4698, 0, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4699, 0, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4700, 0, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4701, 0, 'Brodalumab', 'Crohn Disease', 'The use of brodalumab is contraindicated in patients with Crohn''s disease as this agent may cause worsening of the disease.  It is recommended to discontinue the use of brodalumab if patients develop Crohn''s disease while on treatment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4702, 0, 'Brodalumab', 'Depressive Disorder', 'Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with brodalumab.  Patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior.  Prescribers should weigh the potential risks and benefits before using brodalumab in patients with a history of depression or suicidality.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4703, 0, 'Brodalumab', 'Tuberculosis', 'Brodalumab should not be administered to patients with active tuberculosis infection.  It is recommended to evaluate patients for tuberculosis infection prior to initiating treatment with brodalumab and initiate treatment for latent tuberculosis prior to administering this agent.  Consider anti- tuberculosis therapy prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed.  Closely monitor patients receiving brodalumab for signs and symptoms of active tuberculosis during and after treatment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4704, 0, 'Brodalumab', 'Infections', 'The use of brodalumab of may increase the risk of infections.  When using this agent in patients with a chronic infection or a history of recurrent infection, it is recommended to consider the risks and benefits prior to prescribing brodalumab.  Therapy discontinuation may be considered if a patient develops a serious infection or is not responding to standard therapy for the infection.  Care should be exercised when prescribing this agent to patients with an existing infection.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4705, 0, 'Activated charcoal', 'Intestinal Obstruction', 'Charcoal (with or without sorbitol) should not be used in the presence of a stomach or intestinal obstruction or absence of active bowel sounds.  Delayed GI transit time or constipation can result in failure to excrete a drug- charcoal complex and may result in increased toxicity.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4706, 0, 'Activated charcoal', 'Seizures', 'Charcoal should not be administered in poison victims that are unconscious or having convulsions.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4707, 0, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4708, 0, 'Brivaracetam', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4709, 0, 'Brivaracetam', 'Bronchial Spasm', 'Bronchospasm and angioedema have been reported in patients taking brivaracetam and a hypersensitivity reaction to this agent could predispose patients at risk.  Caution is recommended when using brivaracetam in patients predisposed to bronchospasm and angioedema.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4710, 0, 'Brivaracetam', 'Liver Diseases', 'Brivaracetam is primarily metabolized by hydrolysis in the liver.  A pharmacokinetic study in adult subjects with hepatic cirrhosis, Child-Pugh grades A, B, and C, showed 50%, 57%, and 59% increases in brivaracetam exposure, respectively, compared to matched healthy controls.  Because of increases in brivaracetam exposure, dosage adjustment is recommended for all stages of hepatic impairment as per manufacturer recommendation.  Care and close monitoring is recommended when using this agent in patients with liver disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4711, 0, 'Brivaracetam', 'Kidney Diseases', 'No dose adjustments are needed for patients with impaired renal function.  The use of brivaracetam is not recommended in patients with end-stage renal disease undergoing dialysis as there are no data in this patient population.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4712, 0, 'Bromfenac (ophthalmic)', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4713, 0, 'Bromocriptine', 'Heart Diseases', 'Cardiac irregularities occur infrequently in patients on dopamine agonists.  The initial administration and titration is recommended to occur under close cardiac monitoring in a facility equipped for intensive cardiac care.  Adverse cardiac affects may include palpitation, sinus tachycardia, ventricular tachycardia, extrasystole, atrial flutter or fibrillation, or block of AV conduction.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4714, 0, 'Bromocriptine', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4715, 0, 'Bromocriptine', 'Psychotic Disorders', 'The use of dopamine agonists has been associated with psychiatric effects such as hallucinations, psychosis, confusion, anxiety, mania, hypomania, depression, rapid mood cycling, nightmares, and hypersexuality.  Therapy with dopamine agonists should be administered cautiously in psychotic patients and all patients should be carefully observed for development of depression and suicidal tendencies.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4716, 0, 'Brompheniramine', 'Anticholinergic Syndrome', 'Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects.  In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4717, 0, 'Brompheniramine', 'Asthma', 'It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract.  Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4718, 0, 'Brompheniramine', 'Cardiovascular Diseases', 'Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities.  Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported.  Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4719, 0, 'Brompheniramine', 'Liver Diseases', 'Limited pharmacokinetic data are available for the older, first-generation antihistamines.  Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation.  Therapy with antihistamines should be administered cautiously in such patients.  Lower initial dosages may be appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4720, 0, 'Burosumab', 'Hyperphosphatemia', 'Do not initiate burosumab-twza treatment if serum phosphorus is within or above the normal range for age.  Increases in serum phosphorus to above the upper limit of normal may be associated with an increased risk of nephrocalcinosis.  It is recommended to obtain baseline fasting serum phosphorus levels and to monitor fasting serum phosphorus levels.  Dose interruption and/or dose reduction may be required based on a patient''s serum phosphorus levels.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4721, 0, 'Burosumab', 'Kidney Diseases', 'Burosumab-twza is contraindicated in patients with severe renal impairment or end stage renal disease because these conditions are associated with abnormal mineral metabolism.  The effect of renal impairment on the pharmacokinetics of burosumab-twza is unknown.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4722, 0, 'Burosumab', 'Restless Legs Syndrome', 'The use of burosumab-twza may cause new onset of restless leg syndrome (RLS) or worsen RLS severity.  Care should be exercised when using this agent in patients with existing RLS diagnosis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4723, 0, 'Bumetanide', 'Anuria', 'The use of loop diuretics is contraindicated in patients with anuria.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4724, 0, 'Bumetanide', 'Fibrosis', 'Loop diuretic therapy should be initiated in the hospital under strict observation in patients with liver cirrhosis and ascites.  Sudden alteration of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma in such patients, who are also at increased risk for the development of hypokalemia.  Supplemental potassium and/or concomitant use of an aldosterone antagonist or potassium-sparing agent may help prevent hypokalemia and metabolic alkalosis.  Loop diuretics should be withheld in patients with hepatic coma until the condition improves.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4725, 0, 'Bumetanide', 'Water-Electrolyte Imbalance', 'The use of loop diuretics, particularly at high dosages or during chronic therapy, is commonly associated with loss of electrolytes, including potassium, sodium, chloride, magnesium, and calcium.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Excessive diuresis, as indicated by rapid weight loss, may induce dehydration and hypovolemia, which can result in acute hypotension, orthostasis, circulatory collapse, vascular thrombosis and embolism, and abrupt reduction in glomerular filtration and renal blood flow.  Severe dehydration is most likely to occur in the elderly and patients under prolonged sodium restriction.  Therapy with loop diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected before initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since the development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower diuretic dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.  Similarly, to prevent excessive dehydration and hyponatremia, sodium intake should be liberalized if clinically feasible.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4726, 0, 'Bumetanide', 'Ototoxicity', 'Tinnitus and hearing loss, both reversible and permanent, have been reported with the use of loop diuretics.  Ototoxic effects have generally been associated with rapid intravenous or intramuscular injection, severe renal impairment, unusually high dosages (i.e. several times the usual recommended dosages), and/or concomitant use of other ototoxic agents.  Therapy with loop diuretics should be administered cautiously in patients with preexisting vestibular and/or auditory impairment, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  High-dose parenteral therapy should be administered as controlled infusion.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4727, 0, 'Bumetanide', 'Kidney Diseases', 'Impaired effectiveness and possible delayed excretion of loop diuretics may occur in patients with severe renal dysfunction.  These individuals may require high dosages that are associated with an increased risk of electrolyte abnormalities (hyponatremia, hypochloremic alkalosis, hypokalemia, hypomagnesemia, hypocalcemia) and ototoxicity (tinnitus, hearing loss).  Therapy with loop diuretics should be administered cautiously in patients with significantly impaired renal function.  Prolongation of the dosing intervals may be appropriate to prevent drug accumulation.  The patient should be monitored closely for the signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Excessive diuresis should be avoided as it may induce dehydration and hypovolemia, which can result in an abrupt reduction in glomerular filtration and renal blood flow.  If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, or if renal function becomes progressively worse as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of therapy should be considered.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4728, 0, 'Bumetanide', 'Diabetes Mellitus', 'Loop diuretics may cause hyperglycemia, glycosuria, and alterations in glucose tolerance tests.  Rarely, precipitation of diabetes mellitus has been reported.  Therapy with loop diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4729, 0, 'Bumetanide', 'Hyperuricemia', 'Loop diuretics may decrease the rate of uric acid excretion.  Hyperuricemia can occur but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with loop diuretics should be administered cautiously in such patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4730, 0, 'Bupivacaine (liposome)', 'Cardiovascular Diseases', 'Bupivacaine and other amide- containing products should be used with caution in patients with impaired cardiovascular function, as they may be less able to compensate for functional changes associated with the prolongation of AV conduction produced by these drugs.  Toxic blood concentrations can depress cardiac conductivity and excitability, which can lead to atrioventricular block, ventricular arrhythmias, and cardiac arrest.  In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4731, 0, 'Bupivacaine (liposome)', 'Liver Diseases', 'Amide-type local anesthetics, such as bupivacaine, are metabolized by the liver.  Bupivacaine should be used cautiously in patients with hepatic disease.  Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4732, 0, 'Bupivacaine (liposome)', 'Kidney Diseases', 'Bupivacaine is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4733, 0, 'Cabazitaxel', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4734, 0, 'Cabazitaxel', 'Hepatic Insufficiency', 'Cabazitaxel is extensively metabolized in the liver and is contraindicated in patients with severe hepatic impairment.  Caution and close monitoring is recommended when prescribing this agent to patients with mild or moderate hepatic impairment and dosage reduction should be considered for these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4735, 0, 'Cabazitaxel', 'Bone Marrow Failure Disorders', 'The use of cabazitaxel is contraindicated in patients with neutrophils count less than or equal to 1,500/mm3.  The use of cabazitaxel may cause bone marrow suppression manifested as neutropenia, anemia, thrombocytopenia and/or pancytopenia.  Prophylaxis therapy should be considered in patients with high-risk clinical features (age >65 years, poor performance status, previous episodes of febrile neutropenia, extensive prior radiation ports, poor nutritional status, or other serious comorbidities) that predispose them to increased complications from prolonged neutropenia.  Cautions should be exercised in patients using cabazitaxel with hemoglobin counts of less than 10 g/dL.  It is recommended to monitor complete blood counts on a weekly basis during cycle 1 and before each treatment cycle thereafter so that the dose can be adjusted, if needed.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4736, 0, 'Cabazitaxel', 'Renal Insufficiency', 'Renal failure, sometimes with fatal outcomes has been documented with the use of cabazitaxel in clinical studies and most cases have occurred in association with sepsis, dehydration, or obstructive uropathy.  Care and appropriate measures should be taken when prescribing this agent to these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4737, 0, 'Cabazitaxel', 'Gastrointestinal Diseases', 'Gastrointestinal hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, including fatal outcome, have been reported in patients treated with cabazitaxel.  Risk may be increased with neutropenia, age, steroid use, concomitant use of NSAIDs, anti-platelet therapy or anti-coagulants, and patients with a prior history of pelvic radiotherapy, adhesions, ulceration and GI bleeding.  It is recommended to monitor closely for early manifestations of serious gastrointestinal toxicity and to delay or discontinue treatment if necessary, in particular if patients experience Grade >=3 diarrhea.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4738, 0, 'Cabazitaxel', 'Diseases requiring hemodialysis', 'Cabazitaxel is minimally excreted via the kidney and its use does not require dosage adjustment in patients with renal impairment not requiring hemodialysis.  Patients presenting with end-stage renal disease should be monitored carefully during treatment with cabazitaxel.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4739, 0, 'Cabazitaxel', 'Lung Diseases', 'Interstitial lung disease/pneumonitis and acute respiratory distress syndrome have been reported with the use of cabazitaxel.  Patients with underlying lung disease may be at higher risk for these events.  Acute respiratory distress syndrome may occur in the setting of infection.  Treatment interruption or discontinuation may be necessary if new or worsening of pulmonary symptoms develop.  Close monitoring is recommended.  The benefits of resuming therapy should be carefully evaluated.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4740, 0, 'Buspirone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4741, 0, 'Buspirone', 'Liver Diseases', 'Buspirone is primarily metabolized by the liver and subsequently eliminated by the kidney.  In one study, steady-state area under the plasma concentration-time curve (AUC) of buspirone increased 13-fold in subjects with hepatic impairment and 4-fold in those with renal impairment compared to healthy subjects.  Therapy with buspirone is not recommended in the presence of significantly impaired hepatic or renal function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4742, 0, 'Buspirone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4743, 0, 'Buspirone', 'Substance-Related Disorders', 'In human and animal studies, buspirone has not shown potential for abuse or diversion, and there is no evidence that it causes tolerance or physical and psychological dependence.  However, since it is a CNS-active drug, the manufacturers recommend that therapy with buspirone be administered cautiously in addiction-prone individuals, such as those with a history of alcohol or substance abuse.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4744, 0, 'Cabozantinib', 'Hemorrhage', 'Fatal hemorrhagic events have been reported with the use of cabozantinib.  Therapy with cabozantinib is not recommended in patients that have or are at risk for severe hemorrhage.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4745, 0, 'Cabozantinib', 'Peptic Ulcer Perforation', 'Therapy with cabozantinib should be used with caution in patients who may be at increased risk for gastrointestinal perforation, such as those with a history of diverticulitis.  Patients presenting with new onset of abdominal symptoms should be evaluated promptly for early identification of gastrointestinal perforation.  It is recommended to monitor for symptoms of gastrointestinal perforation or fistula periodically throughout the treatment.  Discontinue cabozantinib in patients who experience a fistula which cannot be appropriately managed or a GI perforation.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4746, 0, 'Cabozantinib', 'Hepatic Insufficiency', 'Increased exposure to cabozantinib has been observed in patients with mild to moderate hepatic impairment.  It is recommended to reduce the cabozantinib dose in patients with mild or moderate hepatic impairment.  The use of cabozantinib is not recommended in patients with severe hepatic impairment.  It is recommended to monitor liver function and urine bilirubin tests periodically during therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4747, 0, 'Cabozantinib', 'Hypertension', 'The use of cabozantinib causes hypertension.  Blood pressure should be well-controlled prior to initiating cabozantinib and monitored and treated as needed with standard anti-hypertensive therapy.  It is recommended to reduce the dose in case of persistent hypertension despite use of anti-hypertensive medications and to discontinue therapy if hypertension is severe and persistent despite these measures.  Discontinue cabozantinib therapy for severe hypertension that cannot be controlled with anti-hypertensive therapy and if there is evidence of hypertensive crisis or severe hypertension despite optimal medical management.  Close monitoring is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4748, 0, 'Cabozantinib', 'Kidney Diseases', 'No dose adjustment is required in patients with mild or moderate renal impairment.  There is no experience with cabozantinib in patients with severe renal impairment.  Care should be exercised in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4749, 0, 'Cabozantinib', 'Posterior Leukoencephalopathy Syndrome', 'Reversible posterior leukoencephalopathy syndrome (RPLS) has been reported in patients receiving cabozantinib.  It is recommended to discontinue therapy in patients developing RPLS.  The safety of reinitiating therapy in patients previously experiencing RPLS is not known.  Care and close monitoring should be considered in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4750, 0, 'Cabozantinib', 'Thromboembolism', 'Arterial and venous thromboembolic events have been reported with the use of cabozantinib.  Use with caution in patients who are at risk, or have a history of these events.  It is recommended to monitor closely for signs and symptoms of thromboembolism.  Discontinue cabozantinib in patients who develop an acute myocardial infarction or any other arterial thromboembolic complication.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4751, 0, 'Cabozantinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4752, 0, 'Butabarbital', 'Alcoholic Intoxication', 'The use of barbiturates is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of barbiturates may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with barbiturates should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4753, 0, 'Butabarbital', 'Substance-Related Disorders', 'Barbiturates have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages.  Abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance to a barbiturate, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with barbiturates.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of barbiturates should be undertaken gradually using a dosage-tapering schedule.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4754, 0, 'Butabarbital', 'Liver Diseases', 'Barbiturates are extensively metabolized by the liver.  The plasma clearance of barbiturates may be decreased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with barbiturates should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Barbiturates are not recommended for use in patients with cirrhosis, hepatic failure, hepatic coma, or other severe hepatic impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4755, 0, 'Butabarbital', 'Porphyrias', 'The use of barbiturates is contraindicated in patients with a history of porphyria.  Barbiturates may exacerbate acute intermittent porphyria or porphyria variegata by inducing the enzymes responsible for porphyrin synthesis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4756, 0, 'Butabarbital', 'Exanthema', 'Skin eruptions may precede rare but potentially fatal barbiturate-induced reactions such as systemic lupus erythematosus and exfoliative dermatitis, the latter of which may be accompanied by hepatitis and jaundice.  Therapy with barbiturates should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to barbiturates.  Barbiturate therapy should be withdrawn promptly at the first sign of a dermatologic adverse effect.  However, cutaneous reactions may proceed to an irreversible stage even after cessation of medication due to the slow rate of metabolism and excretion of barbiturates.  Patients should be advised to promptly report signs that may indicate impending development of barbiturate-related cutaneous lesions, including high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Rashes may be more likely to occur with phenobarbital and mephobarbital.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4757, 0, 'Butabarbital', 'Respiratory Insufficiency', 'Barbiturates may produce severe respiratory depression, apnea, laryngospasm, bronchospasm and cough, particularly during rapid intravenous administration.  In usual hypnotic dosages, the degree of respiratory depression produced is similar to that which occurs during physiologic sleep, while at higher dosages, the rate, depth and volume of respiration may be markedly decreased.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with barbiturates should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used.  Barbiturates, especially injectable formulations, should generally be avoided in patients with sleep apnea, hypoxia, or severe pulmonary diseases in which dyspnea or obstruction is evident.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4758, 0, 'Butabarbital', 'Adrenal Insufficiency', 'Barbiturates, especially phenobarbital, secobarbital and butabarbital, may diminish the systemic effects of exogenous and endogenous corticosteroids via induction of hepatic microsomal enzymes, thereby accelerating the metabolism of corticosteroids.  In addition, barbiturates may interfere with pituitary corticotropin production.  Therapy with barbiturates should be administered cautiously in patients with adrenal insufficiency.  Patients with borderline hypoadrenalism should be monitored closely, and patients receiving steroid supplementation may require an adjustment in dosage when barbiturates are added to or withdrawn from their medication regimen.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4759, 0, 'Butabarbital', 'Depressive Disorder', 'Barbiturates depress the central nervous system and may cause or exacerbate mental depression.  Therapy with barbiturates should be administered cautiously in patients with a history of depression or suicidal tendencies.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4760, 0, 'Butabarbital', 'Hematologic Diseases', 'Hematologic toxicity, including agranulocytosis, thrombocytopenic purpura and megaloblastic anemia, has been reported rarely during use of barbiturates.  Therapy with barbiturates should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Blood counts are recommended prior to and periodically during long-term therapy, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, easy bruising, petechiae, bleeding, pallor, dizziness, or jaundice.  Barbiturate therapy should be discontinued if blood dyscrasias occur.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4761, 0, 'Butabarbital', 'Osteomalacia', 'Rickets and osteomalacia have rarely been reported following prolonged use of barbiturates, possibly due to increased metabolism of vitamin D as a result of enzyme induction by barbiturates.  Long-term therapy with barbiturates should be administered cautiously in patients with vitamin D deficiency.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4762, 0, 'Butabarbital', 'Psychotic Disorders', 'Paradoxical reactions characterized by excitability and restlessness may occur in pediatric patients with hyperactive aggressive disorders.  Such patients should be monitored for signs of paradoxical stimulation during therapy with barbiturates.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4763, 0, 'Bupropion', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4764, 0, 'Bupropion', 'Epilepsy', 'Bupropion is contraindicated in patients with a seizure disorder.  Bupropion can cause seizure; the risk is dose-related.  In 1 study, the seizure incidence was about 0.4% with immediate-release bupropion hydrochloride (HCl) in the range of 300 to 450 mg/day (equal to 348 to 522 mg/day of extended-release bupropion hydrobromide [HBr]); the incidence of seizures increases dramatically at higher dosages (almost 10-fold between 450 and 600 mg/day as bupropion HCl [equal to 522 and 696 mg/day as bupropion HBr]).  The risk of seizures (related to patient factors, clinical situations, and concomitant medications that lower the seizure threshold) should be considered before starting bupropion.  Bupropion is also contraindicated in patients with current/prior diagnosis of bulimia or anorexia nervosa (a higher incidence of seizures was observed in such patients treated with immediate-release bupropion) and in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs.  Bupropion should be administered with caution in patients with conditions that increase the risk of seizure or who have other predisposing conditions including severe head injury; arteriovenous malformation; CNS infection or CNS tumor; severe stroke; metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, hypoxia); excessive use of alcohol, benzodiazepines, sedative/hypnotics, or opiates; use of illicit drugs (e.g., cocaine); abuse/misuse of prescription drugs (e.g., CNS stimulants); diabetes mellitus treated with oral hypoglycemic agents or insulin; use of anorectic agents; and concomitant use of medications that lower the seizure threshold.  The risk of seizure can be reduced if the maximum recommended dosage is not exceeded (e.g., 450 mg/day [as 150 mg 3 times a day] for immediate-release bupropion HCl; 400 mg/day [as 200 mg twice a day] for sustained-release bupropion HCl; 450 mg once a day for extended-release bupropion HCl; 522 mg once a day for extended-release bupropion HBr), and the titration rate is gradual.  Bupropion should be discontinued and should not be restarted if the patient has a seizure.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4765, 0, 'Bupropion', 'Glaucoma, Angle-Closure', 'The pupillary dilation that occurs after use of many antidepressant drugs (including bupropion) can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Patients may want to be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of antidepressants (including bupropion-dextromethorphan) should be avoided in patients with untreated anatomically narrow angles.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4766, 0, 'Bupropion', 'Liver Diseases', 'Bupropion is primarily metabolized by the liver.  The systemic exposure and half-life of bupropion and its metabolites may be increased in patients with liver dysfunction.  A reduced dose and/or dosing frequency should be considered in patients with mild liver dysfunction (Child-Pugh score:  5 to 6).  A dosage reduction is required in patients with moderate to severe liver dysfunction (Child-Pugh score:  7 to 15) who are using a single-ingredient bupropion product; the dosage should not exceed 75 mg/day with immediate-release bupropion hydrochloride (HCl), 100 mg/day or 150 mg every other day with sustained-release bupropion HCl, 150 mg every other day with extended-release bupropion HCl, and 174 mg every other day with extended-release bupropion hydrobromide.  Bupropion-dextromethorphan is not recommended for patients with severe liver dysfunction (Child-Pugh C), and no dose adjustment of bupropion-dextromethorphan is recommended in patients with mild or moderate liver dysfunction (Child-Pugh A or B).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4767, 0, 'Bupropion', 'Bipolar Disorder', 'Bupropion is not approved for the treatment of bipolar depression.  Antidepressant therapy can trigger a manic, mixed, or hypomanic episode; the risk appears increased in patients with bipolar disorder or with risk factors for bipolar disorder.  Before starting bupropion, patients should be screened for history of bipolar disorder and risk factors for bipolar disorder (e.g., family history of bipolar disorder, suicide, or depression).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4768, 0, 'Bupropion', 'Psychotic Disorders', 'Depressed patients treated with bupropion have had various neuropsychiatric signs/symptoms, including delusions, hallucinations, psychosis, concentration disturbance, confusion, and paranoia; some of these patients had a diagnosis of bipolar disorder.  In some cases, these symptoms abated with dose reduction and/or discontinuation of therapy.  Bupropion should be discontinued if such reactions occur.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4769, 0, 'Bupropion', 'Kidney Diseases', 'Bupropion and its metabolites, some of which are pharmacologically active with one-fifth to one-half the potency of the parent drug, are cleared renally and may accumulate in patients with renal dysfunction (GFR less than 90 mL/min) to a greater extent than usual.  Therefore, bupropion should be used with caution in patients with renal dysfunction.  A reduced dose and/or dosing frequency should be considered, and patients should be closely monitored for adverse effects that could indicate high bupropion or metabolite exposures.  Bupropion-dextromethorphan is not recommended for patients with severe renal dysfunction (estimated GFR 15 to 29 mL/min/1.73 m2); dosage adjustment of bupropion-dextromethorphan is recommended in patients with moderate renal dysfunction (estimated GFR 30 to 59 mL/min/1.73 m2).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4770, 0, 'Bupropion', 'Weight Loss', 'The use of bupropion is associated with weight alterations.  Both weight gain and weight loss may occur, although the latter is much more common.  Weight loss greater than 2.27 kg was reported in up to 28% of patients, which may be undesirable in patients suffering from anorexia, malnutrition, or excessive weight loss.  Weight change should be monitored during therapy if bupropion is used in these patients.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4771, 0, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4772, 0, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4773, 0, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4774, 0, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4775, 0, 'Busulfan', 'Infections', 'Busulfan can induce severe and prolonged myelosuppression.  Treatment with busulfan should not be initiated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with busulfan.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4776, 0, 'Busulfan', 'Bone Marrow Failure Disorders', 'Busulfan induces severe and prolonged myelosuppression at the recommended dosage.  Hematopoietic progenitor cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression.  It is recommended to closely monitor complete blood counts, including white blood cell differentials, and quantitative platelet counts daily during treatment and until engraftment is demonstrated.  Extreme caution should be exercised if busulfan is administered in patients whose bone marrow reserve may be compromised by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression, such as fever, sore throat, local infection, bleeding, or symptoms of anemia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4777, 0, 'Busulfan', 'Cardiac Tamponade', 'Cardiac tamponade during high dose busulfan therapy combined with cyclophosphamide has been reported in pediatric patients with thalassemia.  Abdominal pain and vomiting may precede the tamponade.  Cardiac tamponade can result in death and therapy with busulfan should be administered cautiously to patients with thalassemia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4778, 0, 'Busulfan', 'Epilepsy', 'Seizures have been reported in patients receiving high doses of busulfan.  Therapy with busulfan should be administered cautiously to patients with a history of a seizure disorder or head trauma or who are receiving other potentially epileptogenic drugs.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4779, 0, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4780, 0, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4781, 0, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4782, 0, 'Cabergoline', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4783, 0, 'Cabergoline', 'Liver Diseases', 'Cabergoline is extensively metabolized by the liver primarily by hydrolysis.  Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction.  Careful monitoring should be exercised.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4784, 0, 'Caffeine', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4785, 0, 'Caffeine', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4786, 0, 'Caffeine', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4787, 0, 'Caffeine', 'Mental Disorders', 'The use of CNS stimulants can cause psychotic or maniac symptoms, suicidal ideation, aggression and can exacerbate symptoms of behavior disturbance and thought disorder.  Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, specially during treatment initiation and at times of dose changes.  Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder.  All patients receiving treatment should be screened for bipolar disease prior to initiation.  If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered.  CNS stimulants are contraindicated in patients with marked agitation or anxiety.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4788, 0, 'Caffeine', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4789, 0, 'Caffeine', 'Cardiotoxicity', 'Like other methylxanthines, caffeine at high dosages may be associated with positive inotropic and chronotropic effects on the heart.  Caffeine may also produce an increase in systemic vascular resistance, resulting in elevation of blood pressure.  Therapy with products containing caffeine should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or acute myocardial injury.  Some clinicians recommend avoiding caffeine in patients with symptomatic cardiac arrhythmias and/or palpitations and during the first several days to weeks after an acute myocardial infarction.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4790, 0, 'Caffeine', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4791, 0, 'Caffeine', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4792, 0, 'Caffeine', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4793, 0, 'Caffeine', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4794, 0, 'Caffeine', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4795, 0, 'Caffeine', 'Water-Electrolyte Imbalance', 'Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure.  Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4796, 0, 'Caffeine', 'Acid-Base Imbalance', 'Sodium benzoate is structurally similar to salicylates and  mild respiratory alkalosis may occur.  Therapy with sodium benzoate should be administered cautiously in patients with or predisposed to respiratory acidosis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4797, 0, 'Buprenorphine', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4798, 0, 'Buprenorphine', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4799, 0, 'Buprenorphine', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4800, 0, 'Buprenorphine', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4801, 0, 'Buprenorphine', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4802, 0, 'Buprenorphine', 'Myocardial Infarction', 'Opiate partial agonists may increase systemic and pulmonary arterial pressure and systemic vascular resistance, particularly when given by intravenous administration.  Data are available for pentazocine and butorphanol.  Therapy with opiate partial agonists should be administered cautiously and only if the benefit justifies the risk in patients with acute myocardial infarction (especially if accompanied by hypertension or left ventricular failure) or coronary insufficiency.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4803, 0, 'Buprenorphine', 'Substance-Related Disorders', 'Opiate partial agonists have the potential to cause dependence and abuse, particularly in patients with a history of drug abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use, and abrupt cessation or a significant reduction in dosage may precipitate withdrawal symptoms.  Because of their opiate antagonistic effect, withdrawal symptoms may also occur if opiate partial agonists are administered to patients with an opiate dependence or in whom substantial amounts of narcotics have recently been administered.  Therapy with opiate partial agonists is not recommended in patients who are physically dependent on narcotics.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate partial agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4804, 0, 'Buprenorphine', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate partial agonists can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Unless mechanical ventilation is provided, extreme caution is advised when opiate partial agonists are given to patients head injury, intracranial lesions, or a preexisting elevated CSF pressure.  Also, clinicians treating such patients should be aware that opiate partial agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4805, 0, 'Buprenorphine', 'Respiratory Insufficiency', 'Opiate partial agonists may produce respiratory depression by decreasing respiratory drive and increasing airway resistance.  A "ceiling effect" has been noted for these agents, and increasing doses do not produce proportional or further respiratory depression.  However, the duration of effect is prolonged.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate partial agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS or respiratory depression; acute alcohol intoxication; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate partial agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression.  However, in the case of buprenorphine, naloxone may not be effective due to buprenorphine''s slow rate of dissociation from mu receptors.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4806, 0, 'Buprenorphine', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4807, 0, 'Buprenorphine', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4808, 0, 'Buprenorphine', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4809, 0, 'Buprenorphine', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4810, 0, 'Buprenorphine', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4811, 0, 'Buprenorphine', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4812, 0, 'Cabotegravir', 'Depressive Disorder', 'Depressive disorders (including depressed mood, depression, altered mood, mood swings) have been reported with oral cabotegravir.  Depressive disorders (including depressed mood, depression, major depression, altered mood, mood swings, dysphoria, negative thoughts, suicidal ideation/attempt) have been reported with IM cabotegravir-rilpivirine or the individual drug products.  Patients with severe depressive symptoms should be evaluated promptly.  Caution should be used in patients with a history of depression or other psychiatric conditions.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4813, 0, 'Cabotegravir', 'Liver Failure', 'Hepatotoxicity has been reported in patients taking cabotegravir with or without known preexisting hepatic disease or identifiable risk factors.  Patients with underlying liver disease or marked transaminase elevations prior to therapy may be at increased risk for worsening or development of transaminase elevations.  Monitoring of liver chemistries is recommended and cabotegravir should be discontinued if hepatotoxicity is suspected.  Cabotegravir has not been studied in patients with severe liver dysfunction (Child-Pugh C); caution is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4814, 0, 'Cabotegravir', 'Kidney Diseases', 'No dose adjustment of IM or oral cabotegravir is required in patients with mild to moderate or mild to severe renal dysfunction, respectively.  Cabotegravir has not been studied in patients with ESRD not on dialysis; caution is recommended.  IM cabotegravir should be used with caution and with increased monitoring for side effects in patients with severe renal dysfunction or ESRD.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4815, 0, 'Calcifediol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4816, 0, 'Calcifediol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4817, 0, 'Calcifediol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4818, 0, 'Calcifediol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4819, 0, 'Butorphanol', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4820, 0, 'Butorphanol', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4821, 0, 'Butorphanol', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4822, 0, 'Butorphanol', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4823, 0, 'Butorphanol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4824, 0, 'Butorphanol', 'Myocardial Infarction', 'Opiate partial agonists may increase systemic and pulmonary arterial pressure and systemic vascular resistance, particularly when given by intravenous administration.  Data are available for pentazocine and butorphanol.  Therapy with opiate partial agonists should be administered cautiously and only if the benefit justifies the risk in patients with acute myocardial infarction (especially if accompanied by hypertension or left ventricular failure) or coronary insufficiency.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4825, 0, 'Butorphanol', 'Substance-Related Disorders', 'Opiate partial agonists have the potential to cause dependence and abuse, particularly in patients with a history of drug abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use, and abrupt cessation or a significant reduction in dosage may precipitate withdrawal symptoms.  Because of their opiate antagonistic effect, withdrawal symptoms may also occur if opiate partial agonists are administered to patients with an opiate dependence or in whom substantial amounts of narcotics have recently been administered.  Therapy with opiate partial agonists is not recommended in patients who are physically dependent on narcotics.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate partial agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4826, 0, 'Butorphanol', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate partial agonists can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Unless mechanical ventilation is provided, extreme caution is advised when opiate partial agonists are given to patients head injury, intracranial lesions, or a preexisting elevated CSF pressure.  Also, clinicians treating such patients should be aware that opiate partial agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4827, 0, 'Butorphanol', 'Respiratory Insufficiency', 'Opiate partial agonists may produce respiratory depression by decreasing respiratory drive and increasing airway resistance.  A "ceiling effect" has been noted for these agents, and increasing doses do not produce proportional or further respiratory depression.  However, the duration of effect is prolonged.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate partial agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS or respiratory depression; acute alcohol intoxication; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate partial agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression.  However, in the case of buprenorphine, naloxone may not be effective due to buprenorphine''s slow rate of dissociation from mu receptors.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4828, 0, 'Butorphanol', 'Hypertension', 'Butorphanol may increase blood pressure and rarely causes severe hypertension.  Therapy with butorphanol should be administered cautiously in hypertensive patients, particularly when given before surgery or anesthesia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4829, 0, 'Butorphanol', 'Hypotension', 'Butorphanol may rarely induce vasodilation and hypotension with syncope during the first hour following intranasal administration, particularly in patients with a history of similar reactions to opioid analgesic agents.  Therapy with butorphanol should be administered cautiously in patients with circulatory shock, hypovolemia, or a predisposition to hypotension.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4830, 0, 'Butorphanol', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4831, 0, 'Butorphanol', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4832, 0, 'Butorphanol', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4833, 0, 'Butorphanol', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4834, 0, 'Butorphanol', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4835, 0, 'Butorphanol', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4836, 0, 'Calcitriol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4837, 0, 'Calcitriol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4838, 0, 'Calcitriol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4839, 0, 'Calcitriol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4840, 0, 'Calcitriol', 'Diseases requiring dialysis', 'Calcitriol increases inorganic phosphate levels in serum and caution should be used in patients with renal impairment to maintain adequate phosphorus levels and avoid ectopic calcification.  A non-aluminum phosphate-binding compound and a low phosphate diet should be used to control serum phosphorus levels in patients undergoing dialysis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4841, 0, 'Calcitriol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4842, 0, 'Calcipotriol (topical)', 'Hypercalcemia', 'The use of calcipotriene topical preparations is contraindicated in patients with demonstrated hypercalcemia or evidence of vitamin D toxicity.  Calcipotriene is a synthetic vitamin D3 analog.  Systemic absorption of topically applied calcipotriene ranges from less than 1% for the scalp solution to 5% to 6% for the ointment.  Calcipotriene has been reported to be 100 to 200 times less potent in its effects on calcium utilization than natural vitamin D, which facilitates the absorption of calcium in the intestine.  Transient, rapidly reversible elevation of serum calcium has been reported following the topical administration of calcipotriene.  If elevation in serum calcium outside the normal range occurs, treatment should be discontinued until normal calcium levels are restored.  Patients should be advised to contact their physician if they experience early symptoms of hypercalcemia such as weakness, fatigue, somnolence, headache, anorexia, dry mouth, metallic taste, nausea, vomiting, abdominal cramps, constipation, diarrhea, vertigo, tinnitus, ataxia, exanthema, muscle pain, bone pain, and irritability.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4843, 0, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4844, 0, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4845, 0, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4846, 0, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4847, 0, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4848, 0, 'Adalimumab', 'Infections', 'There have been reports of serious infections, including sepsis and opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis with TNF blockers.  Treatment with these agents should not be initiated in patients with an active infection, including clinically important localized infections.  Caution and close monitoring is recommended when considering their use in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.  Administration of these agents should be discontinued if a patient develops a serious infection or sepsis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4849, 0, 'Adalimumab', 'Neoplasms', 'In clinical trials malignancies have been observed in patients receiving TNF-blockers agents.  Patients with psoriasis should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment.  Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy.  Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.  Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers.  Caution should be exercised when considering these agents in the treatment of patients with a history of malignancies or in continuing treatment in patients who develop malignancies while receiving these agents.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4850, 0, 'Adalimumab', 'Neurotoxicity Syndromes', 'The use of TNF blocking agents has been associated with rare cases of CNS manifestations of systemic vasculitis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barr syndrome.  Care should be exercised when considering the use of these agents in patients with neurologic disorders and discontinuing the agent is recommended if these disorders develop during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4851, 0, 'Adalimumab', 'Tuberculosis', 'Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF blocking agents, including patients who have previously received treatment for latent or active tuberculosis.  Cases of active tuberculosis have also occurred in patients being treated with these agents during treatment for latent tuberculosis.  Prior to initiating TNF blocking agents, patients should be screened for latent tuberculosis infection with a tuberculin skin test and periodically during therapy.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with TNF blocking agents.  Anti-tuberculosis therapy should also be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.  Tuberculosis should be strongly considered in patients who develop a new infection during treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4852, 0, 'Adalimumab', 'Heart Failure', 'Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers.  Cases of worsening CHF have also been observed with adalimumab.  Adalimumab has not been formally studied in patients with CHF; however, in clinical trials of another TNF blocker, a higher rate of serious CHF-related adverse reactions was observed.  Exercise caution when using adalimumab in patients who have heart failure and monitor them carefully.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4853, 0, 'Adalimumab', 'Pulmonary Disease, Chronic Obstructive', 'In controlled trials of other TNF blockers, other than adalimumab, in adult patients at higher risk for malignancies (i.e., patients with COPD with a significant smoking history and cyclophosphamide-treated patients with Wegener''s granulomatosis), a greater portion of malignancies occurred in the TNF blocker group compared to the control group.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4854, 0, 'Adalimumab', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients treated with TNF blocking agents.  Caution should be exercised when treating patients who have ongoing or a history of significant hematologic abnormalities.  Discontinuation of therapy should be considered in patients with confirmed significant hematologic abnormalities.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4855, 0, 'Adalimumab', 'Hepatitis B', 'The use of TNF blockers has been associated with reactivation of hepatitis B, in some cases fatal, in patients who were previously infected with the hepatitis B virus (HBV).  Therefore, screening for viral hepatitis should be performed in accordance with published guidelines before starting therapy with these agents.  Monitor patients at risk or with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation.  Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV.  It is recommended to monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following therapy.  In patients who develop HBV reactivation, therapy should be stopped and antiviral therapy with appropriate supportive treatment should be initiated.  The safety of resuming these agents after HBV reactivation is controlled is not known.  Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4856, 0, 'Calcium acetate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4857, 0, 'Calcium acetate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4858, 0, 'Calcium acetate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4859, 0, 'Calcium acetate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4860, 0, 'Calcium acetate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4861, 0, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4862, 0, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4863, 0, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4864, 0, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4865, 0, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4866, 0, 'Calcium gluconate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4867, 0, 'Calcium gluconate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4868, 0, 'Calcium gluconate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4869, 0, 'Calcium gluconate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4870, 0, 'Calcium gluconate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4871, 0, 'Canagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4872, 0, 'Canagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4873, 0, 'Canagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4874, 0, 'Canagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4875, 0, 'Canakinumab', 'Infections', 'There have been reports of serious infections, including infections with opportunistic pathogens, and reactivation of latent infections in patients receiving interleukin inhibitors.  Treatment with these agents should not be initiated in patients with an active infection until the infection resolves or is adequately treated.  Caution is recommended when considering the use of interleukin inhibitors in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4876, 0, 'Canakinumab', 'Tuberculosis', 'Before initiating certain interleukin inhibitors, patients should be screened for latent tuberculosis infection with a tuberculin skin test.  Do not administer these agents to patients with an active tuberculosis infection.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy.  Anti-tuberculosis therapy should be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4877, 0, 'Cannabidiol', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4878, 0, 'Cannabidiol', 'Hepatic Insufficiency', 'Because of the risk of hepatocellular injury, serum transaminases (ALT and AST) and total bilirubin levels should be measured in all patients prior to starting treatment with cannabidiol.  Cannabidiol causes dose-related elevations of liver transaminases, and in controlled studies 13% of patients receiving treatment had elevations above 3 times the ULN.  Caution and monitoring is advised in patients with hepatic impairment, which can be at increased risk.  Dose adjustment is recommended in patients with moderate (Child-Pugh B) hepatic impairment or severe (Child-Pugh C) hepatic impairment.  It may be necessary to have slower dose titration in patients with moderate or severe hepatic impairment than in patients without hepatic impairment.  If a patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine), promptly measure serum transaminases and total bilirubin and interrupt or discontinue treatment with cannabidiol, as appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4879, 0, 'Adapalene (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4880, 0, 'Adapalene (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4881, 0, 'Carfilzomib', 'Tumor Lysis Syndrome', 'Cases of tumor lysis syndrome (TLS), including fatal outcomes, have been reported in patients receiving carfilzomib.  Patients with multiple myeloma and a high tumor burden should be considered at a greater risk for TLS.  Ensure that patients are well hydrated before administration of therapy in Cycle 1, and in subsequent cycles as recommended by the manufacturer.  Consider uric acid-lowering drugs in patients at risk for TLS.  It is recommended to monitor for evidence of TLS during treatment and manage promptly, including interruption of therapy until resolution of TLS.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4882, 0, 'Carfilzomib', 'Heart Diseases', 'Carfilzomib can cause new onset or worsening of preexisting cardiac failure, restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction.  Patients with preexisting heart problems might be at a greater risk of cardiac toxicity.  It is recommended to monitor patients for clinical signs or symptoms of cardiac failure or cardiac ischemia.  Evaluate promptly if cardiac toxicity is suspected.  Withhold therapy for Grade 3 or 4 cardiac adverse events until recovery, and consider whether to restart at 1 dose level reduction based on a benefit/risk assessment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4883, 0, 'Carfilzomib', 'Dyspnea', 'Dyspnea was reported in patients treated with carfilzomib.  Evaluate dyspnea to exclude cardiopulmonary conditions including cardiac failure and pulmonary syndromes.  Withhold therapy with carfilzomib for Grade 3 or 4 dyspnea until resolved or returned to baseline.  Consider whether to restart therapy based on a benefit/risk assessment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4884, 0, 'Carfilzomib', 'Hemorrhage', 'Fatal or serious cases of hemorrhage have been reported in patients treated with carfilzomib.  Hemorrhage has been reported in patients having either low or normal platelet counts.  Hemorrhage has also been reported in patients who were not on antiplatelet therapy or anticoagulation.  Care should be exercised when using this agent in patients at risk of hemorrhagic events.  Promptly evaluate signs and symptoms of blood loss.  It is recommended to monitor platelet counts frequently during treatment and to reduce or withhold dose as appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4885, 0, 'Carfilzomib', 'Liver Failure', 'Cases of hepatic failure, including fatal cases, have been reported in patients receiving treatment with carfilzomib.  The pharmacokinetics and safety of carfilzomib were evaluated in patients with normal hepatic function, or mild, moderate, or severe hepatic impairment.  The AUC of carfilzomib increased by approximately 50% in patients with mild and moderate hepatic impairment compared to patients with normal hepatic function.  PK data were not collected in patients with severe hepatic impairment.  It is recommended to reduce the dose of carfilzomib by 25% in patients with mild or moderate hepatic impairment.  Dosing recommendation cannot be made for patients with severe hepatic function.  Monitor liver enzymes regularly, regardless of baseline values, and modify dose based on toxicity.  Therapy with this agent can cause increased serum transaminases.  Monitor liver enzymes regularly, regardless of baseline values.  It is recommended to reduce or withhold dose as appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4886, 0, 'Carfilzomib', 'Hypertension', 'The use of carfilzomib has been associated with hypertension, including hypertensive crisis and hypertensive emergency.  It is recommended to monitor blood pressure regularly in all patients, especially in hypertensive patients.  Care should be taken and if hypertension cannot be adequately controlled, withhold therapy and consider whether to restart therapy based on a benefit/risk assessment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4887, 0, 'Carfilzomib', 'Posterior Leukoencephalopathy Syndrome', 'Cases of posterior reversible encephalopathy syndrome (PRES) have been reported with the use carfilzomib.  Discontinue therapy if PRES is suspected and evaluate.  Care should be exercised as the safety of reinitiating carfilzomib therapy in patients previously experiencing PRES is not known.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4888, 0, 'Carfilzomib', 'Hypertension, Pulmonary', 'Pulmonary arterial hypertension was reported in patients treated with carfilzomib.  It is recommended to evaluate patients with cardiac imaging and/or other tests as indicated.  Care should be exercised in patients with existing pulmonary hypertension.  Withhold carfilzomib therapy for pulmonary hypertension until resolved or returned to baseline, and consider whether to restart based on a benefit/risk assessment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4889, 0, 'Carfilzomib', 'Lung Diseases', 'The use of carfilzomib has been associated with pulmonary toxicity.  Patients presenting pulmonary symptoms should be carefully assessed for pulmonary toxicity.  It is recommended to discontinue treatment in the event of drug-induced pulmonary toxicity.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4890, 0, 'Carfilzomib', 'Renal Insufficiency', 'Cases of acute renal failure have occurred in patients receiving carfilzomib.  The risk was greater in patients with a baseline reduced estimated creatinine clearance.  It is recommended to monitor renal function with regular measurement of the serum creatinine and/or estimated creatinine clearance.  Consider reducing or withholding dose as appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4891, 0, 'Carfilzomib', 'Purpura, Thrombotic Thrombocytopenic', 'Cases of thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) have been reported with the use of carfilzomib.  Monitor for signs and symptoms of TTP/HUS.  If the diagnosis is suspected, stop therapy and evaluate patients.  If the diagnosis of TTP/HUS is excluded, therapy may be restarted.  The safety of reinitiating carfilzomib therapy in patients previously experiencing TTP/HUS is not known.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4892, 0, 'Carfilzomib', 'Thrombophilia', 'Carfilzomib should be used with caution in patients with a history of venous thromboembolic events, including deep venous thrombosis and pulmonary embolism.  Thromboprophylaxis is recommended for patients being treated with the combination of carfilzomib with dexamethasone or with lenalidomide plus dexamethasone.  The thromboprophylaxis regimen should be based on an assessment of the patient''s underlying risks.  Patients using oral contraceptives or a hormonal method of contraception associated with a risk of thrombosis should consider an alternative method of effective contraception during treatment with carfilzomib in combination with dexamethasone or lenalidomide plus dexamethasone.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4893, 0, 'Capmatinib', 'Liver Diseases', 'Capmatinib is primarily metabolized by CYP450 3A4 and aldehyde oxidase and its use may cause hepatotoxicity.  Assess liver function tests, including ALT, AST, and total bilirubin before administering capmatinib, every 2 weeks during the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop increased transaminases or bilirubin.  Caution when using this agent in patients with liver disorder or a disorder of bilirubin metabolism.  Withhold, reduce the dose, or permanently discontinue capmatinib based on severity of adverse reactions.  No clinically significant effects on the pharmacokinetic parameters of capmatinib were identified in patients with mild, moderate or severe hepatic impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4894, 0, 'Capmatinib', 'Lung Diseases', 'The use of capmatinib may cause interstitial lung disease (ILD)/pneumonitis.  Exercise care when using this agent in patients with disorders of the lung.  It is recommended to monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis.  Immediately withhold treatment with capmatinib in patients with suspected ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/pneumonitis are identified.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4895, 0, 'Capmatinib', 'PHOTOPAROXYSMAL RESPONSE 1', 'The use of capmatinib may cause photosensitivity reactions.  Exercise care when using this agent in patients predisposed to photosensitivity reactions or with a history of skin cancer.  It is recommended that patients use precautionary measures against ultraviolet exposure such as use of sunscreen or protective clothing during treatment with capmatinib.  Advise patients to limit direct ultraviolet exposure during treatment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4896, 0, 'Capmatinib', 'Kidney Diseases', 'No clinically significant effects on the pharmacokinetic parameters of capmatinib were identified in patients with mild to moderate renal impairment.  Therefore, no dosage adjustment is recommended in patients with mild or moderate renal impairment.  Exercise care when using capmatinib in patients with severe renal impairment as it has not been studied in these patient population.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4897, 0, 'Capecitabine', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4898, 0, 'Capecitabine', 'Coronary Artery Disease', 'Capecitabine can cause cardiotoxicity including myocardial infarction, ischemia, angina, dysrhythmias, cardiac failure, sudden death, electrocardiographic changes and cardiomyopathy.  These adverse reactions can be more common in patients with a prior history of coronary artery disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4899, 0, 'Capecitabine', 'Bone Marrow Failure Disorders', 'Capecitabine is metabolized by the liver to fluorouracil (5-FU).  Fluorouracil induces bone marrow suppression.  Leukopenia, thrombocytopenia, and anemia, some severe, have been reported with capecitabine therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4900, 0, 'Capecitabine', 'Kidney Diseases', 'Capecitabine is contraindicated in patients with severe renal impairment (creatinine clearance below 30 mL/min).  Patients with moderate renal impairment at baseline require a dose reduction.  Patients with mild and moderate impairment should be carefully monitored for adverse reactions and prompt interruption of therapy with subsequent dose adjustment might be required depending on the developed adverse events.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4901, 0, 'Capecitabine', 'Dehydration', 'Dehydration has been observed in patients receiving capecitabine and it may cause acute renal failure which could be fatal.  Patients with asthenia, anorexia, nausea, vomiting or diarrhea may rapidly become dehydrated.  Patients should be monitored to prevent and correct dehydration at the onset.  If dehydration grade 2 or higher occurs, treatment should be interrupted until dehydration is corrected.  Since capecitabine can also induce diarrhea, sometimes severe, patients should be carefully monitored and receive fluid and electrolyte replacement.  Standard antidiarrheal treatments are recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4902, 0, 'Capecitabine', 'Liver Diseases', 'Capecitabine is extensively metabolized by the liver.  In patients with mild to moderate liver dysfunction due to liver metastases the Cmax and AUC of capecitabine were increased 60%.  These patients should be carefully monitored when capecitabine is administered.  The effect of severe hepatic dysfunction on capecitabine has not been assessed.  Clinical monitoring of hepatic function is recommended for patients with compromised hepatic function.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4903, 0, 'Captopril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4904, 0, 'Captopril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4905, 0, 'Captopril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4906, 0, 'Captopril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4907, 0, 'Captopril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4908, 0, 'Captopril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4909, 0, 'Captopril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4910, 0, 'Captopril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4911, 0, 'Cefazolin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4912, 0, 'Cefazolin', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4913, 0, 'Cefazolin', 'Heart Failure', 'Parenteral cefazolin sodium contains approximately 46 mg (2 mEq) of sodium per each gram of cefazolin activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4914, 0, 'Cefazolin', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4915, 0, 'Cefazolin', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4916, 0, 'Cefazolin', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4917, 0, 'Carboplatin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4918, 0, 'Carboplatin', 'Hemorrhagic Disorders', 'The use of carboplatin is contraindicated in patients with significant bleeding.  Carboplatin causes severe myelosuppression and dose-dependent thrombocytopenia.  Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, epistaxis, hemoptysis, hematuria, and melena.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4919, 0, 'Carboplatin', 'Bone Marrow Failure Disorders', 'The use of carboplatin is contraindicated in patients with severe myelosuppression.  Carboplatin induces dose-dependent leukopenia, thrombocytopenia, and anemia, which is cumulative and also dose limiting.  Therapy with carboplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation, whose marrow function is recovering from previous cytotoxic therapy, or in patients with compromised renal function.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Peripheral blood counts should be frequently monitored during carboplatin injection treatment and, when appropriate, until recovery is achieved.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4920, 0, 'Carboplatin', 'Kidney Diseases', 'Carboplatin is primarily eliminated by the kidney.  Total body and renal clearance of carboplatin are reduced in patients with a creatinine clearance < 60 mL/min.  Patients with impaired renal function are at increased risk for toxicity, particularly myelosuppression.  Therapy with carboplatin should be administered cautiously in patients with compromised renal function.  Clinical monitoring of renal function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4921, 0, 'Carboplatin', 'Peripheral Nervous System Diseases', 'Mild peripheral neuropathy has been noted during carboplatin therapy and is characterized most frequently by paresthesias.  Patients older than 65 years and/or previously treated with cisplatin appear to be at increased risk for peripheral neuropathy.  There was no worsening of cisplatin symptoms in 70% of patients who received carboplatin as secondary treatment.  Therapy with carboplatin should be administered cautiously in patients with or predisposed to neuropathy.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4922, 0, 'Cefditoren', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4923, 0, 'Cefditoren', 'Systemic carnitine deficiency', 'The use of cefditoren pivoxil is contraindicated in patients with carnitine deficiency or congenital metabolic disorders that may result in clinically significant carnitine deficiency, since the drug can cause renal excretion of carnitine.  Cefditoren pivoxil is hydrolyzed by esterases in vivo to cefditoren and pivalate, the latter of which is primarily eliminated (> 99%) through renal excretion as pivaloylcarnitine.  In healthy volunteers given cefditoren pivoxil for 10 to 14 days, plasma carnitine concentrations decreased by an average of 39% to 63% depending on dosage and returned to the normal control range within 7 to 10 days after discontinuation of cefditoren pivoxil.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4924, 0, 'Cefditoren', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4925, 0, 'Cefditoren', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4926, 0, 'Cefditoren', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4927, 0, 'Cefditoren', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4928, 0, 'Cefepime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4929, 0, 'Cefepime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4930, 0, 'Cefepime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4931, 0, 'Cefepime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4932, 0, 'Cefepime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4933, 0, 'Caspofungin', 'Liver Diseases', 'Caspofungin is primarily metabolized by the liver.  In a single-dose study, plasma concentrations of caspofungin after a 70 mg dose in patients with mild hepatic impairment (Child-Pugh score 5 to 6) increased by approximately 55% compared to healthy control subjects, whereas patients with moderate hepatic impairment (Child-Pugh score 7 to 9) had an average plasma increase of 76%.  In a 14-day multiple-dose study (70 mg on the first day followed by 50 mg daily), plasma concentrations in patients with mild hepatic impairment were increased modestly by about 19% to 25% on days 7 and 14 relative to healthy control subjects.  No dosage adjustment is necessary in patients with mild hepatic impairment.  For patients with moderate hepatic impairment, a reduced dosage of 35 mg/day is recommended following the initial 70 mg loading dose.  There is no clinical experience with caspofungin in patients with severe hepatic impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4934, 0, 'Cefiderocol', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4935, 0, 'Cefiderocol', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4936, 0, 'Cefiderocol', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4937, 0, 'Cefixime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4938, 0, 'Cefixime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4939, 0, 'Cefixime', 'Diabetes Mellitus', 'The cephalosporins, cefixime and cefdinir, have been reported to cause false-positive reactions for ketones in the urine with tests using nitroprusside, but not with tests using nitroferricyanide.  Clinicians should be cognizant of this interaction when prescribing or administering either of these agents to patients with diabetes.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4940, 0, 'Cefixime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4941, 0, 'Cefixime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4942, 0, 'Afatinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4943, 0, 'Capreomycin', 'Hearing Loss', 'Capreomycin is potentially ototoxic, both to vestibular and to auditory functions.  The risk is greatest in patients receiving large doses for prolonged periods of time.  Its use in patients with preexisting auditory impairment must be undertaken with great caution, and the risk of additional cranial nerve VIII impairment should be weighed against the benefits to be derived from therapy.  Audiometric measurements and assessment of vestibular function should be performed prior to initiation of therapy with at regular intervals during treatment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4944, 0, 'Capreomycin', 'Kidney Diseases', 'Renal injury, with tubular necrosis, elevation of the blood urea nitrogen (BUN) or serum creatinine, and abnormal urinary sediment, has been noted with the use of capreomycin.  Its use in patients with renal insufficiency must be undertaken with great caution, and the risk of additional renal injury should be weighed against the benefits to be derived from therapy.  Capreomycin for injection is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  Patients with reduced renal function should have dosage reduction based on creatinine clearance using the guidelines proposed by the manufacturers (see prescribing information).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4945, 0, 'Capreomycin', 'Hypokalemia', 'The use of capreomycin has been associated with producing hypokalemia.  Therapy with capreomycin should be administered cautiously to patients with hypokalemia.  Frequent monitoring of serum potassium along with appropriate electrolyte replacement is  recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4946, 0, 'Capreomycin', 'Liver Failure', 'Abnormal results in liver function tests have occurred in many persons receiving capreomycin for injection in combination with other antituberculosis agents that also are known to cause changes in hepatic function.  The role of capreomycin for injection in producing these abnormalities is not clear; however, periodic determinations of liver function are recommended.  Caution and close monitoring is advised in patient with liver impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4947, 0, 'Capreomycin', 'Hypocalcemia', 'Hypomagnesemia and hypocalcemia may occur during therapy with capreomycin.  These serum electrolyte levels should be determined frequently during therapy.  Caution and close monitoring is advised in patients with baseline low levels of magnesium or calcium.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4948, 0, 'Cariprazine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4949, 0, 'Cariprazine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4950, 0, 'Cariprazine', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4951, 0, 'Cariprazine', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4952, 0, 'Cariprazine', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4953, 0, 'Cariprazine', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4954, 0, 'Cariprazine', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4955, 0, 'Cariprazine', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4956, 0, 'Cariprazine', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4957, 0, 'Cariprazine', 'Kidney Diseases', 'Therapy with some atypical antipsychotic agents should be administered cautiously in patients with renal impairment and the dosage should be reduced accordingly.  These agents are not recommended in patients with severe renal impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4958, 0, 'Cariprazine', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4959, 0, 'Cariprazine', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4960, 0, 'Cariprazine', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4961, 0, 'Adefovir dipivoxil', 'Kidney Diseases', 'Adefovir is primarily eliminated by the kidney via glomerular filtration and active tubular secretion.  Renal impairment, including acute renal failure and Fanconi syndrome, has been reported with adefovir use.  Close monitoring of renal function and lengthening the dosing interval are recommended for patients with creatinine clearance less than 50 mL/min.  Creatinine clearance should be calculated in all patients before starting adefovir treatment and during treatment when clinically appropriate.  Routine monitoring of serum creatinine and phosphorus is recommended for patients at risk of or with a history of renal dysfunction.  Safety and effectiveness have not been evaluated in patients with renal insufficiency using dose adjustments; therefore, the benefit of adefovir treatment should be weighed against the risk of renal toxicity.  Adefovir should be avoided in patients who are currently using or have recently used nephrotoxic drugs.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4962, 0, 'Cefaclor', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4963, 0, 'Cefaclor', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4964, 0, 'Cefaclor', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4965, 0, 'Cefaclor', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4966, 0, 'Cefaclor', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4967, 0, 'Adenosine', 'Sick Sinus Syndrome', 'The use of adenosine is contraindicated in patients with second- or third-degree AV block, sick sinus syndrome, or symptomatic bradycardia in the absence of a functional artificial pacemaker.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4968, 0, 'Adenosine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4969, 0, 'Adenosine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4970, 0, 'Adenosine', 'Asthma', 'Adenosine induces mast cell degranulation and histamine release.  Bronchoconstriction has been reported in patients with asthma during therapy with adenosine.  Therapy with adenosine should be administered cautiously in patients with obstructive lung disease not associated with bronchoconstriction (emphysema or bronchitis) and should be avoided in patients with bronchoconstriction or bronchospasm (asthma).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4971, 0, 'Carvedilol', 'Atrioventricular Block', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4972, 0, 'Carvedilol', 'Shock, Cardiogenic', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with hypotension or cardiogenic shock.  Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to further depress cardiac output and blood pressure, which can be detrimental in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4973, 0, 'Carvedilol', 'Diseases requiring hemodialysis', 'Therapy with beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in patients requiring hemodialysis.  When given after dialysis, hemodynamic stability should be established prior to drug administration to avoid marked falls in blood pressure.  The hemodynamic status should be closely monitored before and after the dose.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4974, 0, 'Carvedilol', 'Hypersensitivity', 'The use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4975, 0, 'Carvedilol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4976, 0, 'Carvedilol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4977, 0, 'Carvedilol', 'Heart Failure', 'The use of carvedilol is contraindicated in patients with NYHA class IV decompensated heart failure.  Sympathetic stimulation may be important in maintaining the hemodynamic function in these patients, thus beta-blockade can worsen the heart failure.  Carvedilol may be used for the treatment of mild to moderate (NYHA class II or III) heart failure of ischemic or cardiomyopathic origin in patients receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4978, 0, 'Carvedilol', 'Liver Diseases', 'Carvedilol is extensively metabolized by the liver.  Patients with cirrhosis have demonstrated significantly higher plasma concentrations (approximately 4 to 7-fold) of carvedilol compared to healthy individuals.  The use of carvedilol is contraindicated in patients with severe hepatic impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4979, 0, 'Carvedilol', 'Liver Failure', 'The use of carvedilol is contraindicated in patients with severe hepatic impairment.  Compared to healthy subjects, patients with severe liver impairment (cirrhosis) exhibit a 4- to 7-fold increase in carvedilol levels.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4980, 0, 'Carvedilol', 'Asthma', 'Some beta-adrenergic receptor blocking agents (i.e., non-cardioselective beta-blockers) are contraindicated in patients with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease.  In general, beta-adrenergic receptor blocking agents should not be used in patients with bronchospastic diseases.  Beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  If beta-blocker therapy is necessary in these patients, an agent with beta-1 selectivity (e.g., atenolol, metoprolol, betaxolol) is considered safer, but should be used with caution nonetheless.  Cardioselectivity is not absolute and can be lost with larger doses.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4981, 0, 'Carvedilol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4982, 0, 'Carvedilol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4983, 0, 'Carvedilol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4984, 0, 'Carvedilol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4985, 0, 'Carvedilol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4986, 0, 'Carvedilol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4987, 0, 'Carvedilol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4988, 0, 'Carvedilol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4989, 0, 'Carvedilol', 'Kidney Diseases', 'The use of carvedilol has rarely resulted in deterioration of renal function in patients with congestive heart failure.  Patients with low blood pressure (systolic BP < 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal impairment may be at greater risk.  In these patients, monitoring of renal function is recommended during dosage titration, and the dosing reduced or discontinued accordingly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4990, 0, 'Carvedilol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4991, 0, 'Carteolol (ophthalmic)', 'Asthma', 'Ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with a current or past history of bronchial asthma or chronic obstructive pulmonary disease.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the respiratory tract, beta blockade may adversely affect pulmonary function by counteracting the bronchodilation produced by catecholamine stimulation of beta-2 receptors.  Although agents with beta-1 selectivity (e.g., betaxolol) are considered safer in patients with bronchospastic diseases, cardioselectivity is not absolute and may be lost with larger doses or higher plasma levels.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4992, 0, 'Carteolol (ophthalmic)', 'Atrioventricular Block', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac function in such patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4993, 0, 'Carteolol (ophthalmic)', 'Shock, Cardiogenic', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with cardiogenic shock.  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In cardiac tissues, beta blockade causes a reduction in inotropic as well as chronotropic activity, which may further depress cardiac output and blood pressure in such patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4994, 0, 'Carteolol (ophthalmic)', 'Heart Failure', 'The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with overt congestive heart failure (CHF).  Topically applied beta-blockers are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  Since sympathetic stimulation may be important in maintaining the hemodynamic function in patients with CHF, beta blockade can worsen the heart failure.  However, therapy with ophthalmic beta-blockers can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates.  Beta-blockers should be discontinued if cardiac failure develops or worsens during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4995, 0, 'Carteolol (ophthalmic)', 'Diabetes Mellitus', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4996, 0, 'Carteolol (ophthalmic)', 'Hypersensitivity', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  The use of beta-blockers in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens.  The frequency and/or severity of attacks may be increased during beta-blocker therapy.  In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4997, 0, 'Carteolol (ophthalmic)', 'Hyperthyroidism', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask some symptoms of hyperthyroidism such as tachycardia, anxiety, tremor, and heat intolerance.  Abrupt withdrawal of beta-blocker therapy in thyrotoxic patients may exacerbate symptoms of hyperthyroidism or precipitate a thyroid storm.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with or suspected of having hyperthyroidism.  Cessation of beta-blocker therapy, when necessary, should occur gradually over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4998, 0, 'Carteolol (ophthalmic)', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., timolol, carteolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Since topically applied beta-blockers are systemically absorbed and may produce clinically significant systemic effects even at low or undetectable plasma levels, therapy with ophthalmic beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (4999, 0, 'Carteolol (ophthalmic)', 'Myasthenia Gravis', 'Topically applied beta-adrenergic receptor blocking agents (aka beta-blockers) are systemically absorbed, with the potential for producing clinically significant systemic effects even at low or undetectable plasma levels.  In the nervous and musculoskeletal systems, beta blockade may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (5000, 0, 'Carisoprodol', 'Porphyrias', 'The use of carisoprodol is contraindicated in patients with acute intermittent porphyria.  Carisoprodol is partially metabolized to the pharmacologically active meprobamate, which has been reported to precipitate acute attacks of porphyria in susceptible patients.', '3', 'DDInter');
